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 To meet the body’s metabolic needs, adipocytes release fatty acids and glycerol through the 
action of neutral lipases. Lipids are also key local regulators of immune function. During obesity, 
triglycerides accumulate in adipose tissue macrophages and this accumulation is associated with 
systemic metabolic complications including insulin resistance and atherosclerosis.  
 
While studying the accumulation of lipid in adipose tissue macrophages, we discovered a 
secondary pathway of lipid release from adipocytes that occurs via exosomes and is independent of 
canonical lipolysis. Bone-Marrow-Derived Macrophages (BMDMs) cultured with lipase-deficient adipose 
tissue (as compared to WT) accumulate similar levels of neutral lipid, despite a marked decrease in free 
fatty acid release from these tissues. Adipocytes release exosome-sized vesicles (AdExos) that contain 
high levels of neutral lipid, that can be found in both adipose tissue conditioned medium and in circulation. 
Lean animals release ~ 1% of their adipocyte lipid content per day via exosomes; this rate more than 
doubles with obesity.  
 
AdExos are taken up almost exclusively by local macrophages and are sufficient to induce the 
lipid-loading seen in BMDMs co-cultured with adipose tissue. AdExos and associated factors are 
sufficient to foster differentiation of bone marrow precursors into adipose tissue macrophage-like cells by 
inducing multinucleation, increased lysosomal program, increased ATM-associated gene expression, and 
increased lipid content. Our findings suggest both a novel pathway of local lipid release and a mechanism 
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1.1 Adipose Tissue 
 
Energy is a cornerstone of life. Nearly all biological functions require energy. Having stores of 
energy provides flexibility in the relationship between when energy is consumed and when energy is 
expended, greatly increasing the ability to survive. Keeping large energy stores within cells that have 
other specified roles, however, would likely hamper cellular functions. The development of specialized 
tissue for energy storage, allows others tissues and cells to function without the burden associated with 
regulated storage and release of calories.  In humans and other mammals, adipose tissue serves this 
essential function (1). Adipocytes are the primary storage cells of adipose tissue.  As a storage depot for 
energy, adipose tissue must respond rapidly to any changes in the energy state of an organism. In times 
of energy excess, stores must expand efficiently; during periods of deficit, mobilization of energy stores 
must occur and be commensurate with the energy needs of tissues.   
 
Consistent with adipocytes’ essential function, much of the molecular machinery that regulates 
the storage of calories as lipids is conserved among invertebrates and vertebrates alike (2-4).  
Maintaining a sufficient supply of metabolic substrates during periods of negative energy balance, 
requires integration with signals from other tissues and a coordinated response. Over the last quarter 
century it has become apparent that this coordinate response to changes in energy balance includes 
hormonal signals from adipose tissue (5). In addition to leptin, which has been established as a true 
hormone,  fat secretes more than 600 different molecules many of which have been implicated in glucose 
homeostasis, whole-body metabolism, appetite, and reproduction (6-8). While it is likely that only a small 
percentage of these are truly hormones, many investigators believe that many of these secreted 
molecules act locally to maintain adipose tissue function and lipid homeostasis (9). Adipose tissue also 
plays a role, especially in small mammals, in thermoregulation, both through uncoupling of respiration and 





Impaired function of adipose tissue is implicated in many disorders. Rare mutations that affect 
key functions of adipocytes have profound, protean effects beyond adipose tissue.  For example, 
mutations in AGPAT2 which encodes a gene required for the generation of phosphatidic acid, severely 
limits adipocyte development leading to near absence of fat and a syndrome of congenital generalized 
lipodystrophy, characterized by severe hepatic steatosis and insulin resistance (12-14).  Much more 
commonly, expansion of adipose tissue that occurs in obesity changes both the character and function of 
adipose tissue, and although the alterations are more subtle, the adverse sequela affects nearly all organ 
systems, increasing rates of diabetes, autoimmune disease, hepatic steatosis, more than a dozen 
cancers, gallbladder disease and dementia (15-19).  Understanding the normal function of adipose tissue 
is required before we can fully understand these complications of altered function.   
 
1.2 The Obesity Epidemic 
 
Obesity is chronic disorder broadly defined as a state of excess body-fat mass that induces 
pathology. At its most basic level, obesity develops due to an imbalance of energy homeostasis: excess 
energy intake relative to energy expenditure.  There has been an epidemic of obesity in the last several 
decades, starting in the industrialized nations and spreading to the developing world (20).   Epidemiologic 
evidence has implicated the availability of inexpensive foods of high caloric density and decreased 
requirements for energy expenditure (21).   The scope of the problem is staggering. Body Mass Index 
(BMI) is a easy to measure surrogate of adiposity that is especially useful in population studies.  The BMI 
body mass divided by height-squared. In SI units normal BMI in adults for the US have been defined as 
between18.5 kg/m2 and 25 kg/m2, s with BMIs between 25 kg/m2 and 30 kg/m2 considered overweight, 
and those with a BMI > 30 kg/m2 considered obese. Currently, ~70% of the adult US population has a BMI 
above 25 kg/m2, and ~33% of the US population has a BMI above 30 kg/m2 (22). By the year 2030, it is 





A primary reason that this high and increasing rate of obesity is a health problem, is that obesity 
is associated with many co-morbidities.  Obesity greatly increases one’s risk for developing insulin 
resistance, Type 2 Diabetes Mellitus (T2DM), cardiovascular disease, cancer, stroke, fatty liver disease, 
high blood pressure, autoimmune disorders, dementia, affective disorders and infertility. Obesity and 
overweight together have become the second largest cause of preventable death in the US, behind only 
tobacco use, and the fifth largest global risk factor for death overall (24-27). Extreme obesity (BMI > 40 
kg/m2), which is also becoming more prevalent, is estimated to shorten life expectancy by as much as 14 
years (28).  In 2010, the estimated additional cost of healthcare for each patient with obesity in the US 
was $3500 per year, with a total aggregate cost of $315.8 billion spent on adult obese patients (29-31). 
This figure represents an increase in spending of 48.7% in a five-year period, as an estimated $212.4 
billion was spent in 2005 (32, 33). Obesity is also known to associate with indirect costs to society related 
increased work absenteeism and decreased work (34).  There are economic benefits to be had from 
successful obesity therapies.  
 
Current medical treatment for obesity have had minimal effects in reducing the epidemic of 
obesity. Obese patients are typically advised to undertake a diet and exercise program, sometimes with 
intensive counseling and support. These therapies rarely provide sustained weight loss, and when initially 
effective, patients typically regain most of the lost weight over the subsequent 12-36 months (35).  
Incretin based therapies, including those that increase the action/signaling of GLP1 and GIP are 
approved and some have additional demonstrated cardiovascular benefit, but thus far have had modest 
overall effect to curb the tide of obesity (36-38).  More recently and surprisingly, a new class of anti-
diabetic drugs, SGLT2 inhibitors lead to modest weight loss and also reduce cardiovascular complications 
(39).  However, it is not clear that these medical benefits are secondary to the small weight loss.  The 
most effective intervention available currently is bariatric surgery.  Several different surgical approaches 
have been shown to lead to substantial and durable weight loss in the majority of patients (40-42).  
However, even in the face of these interventions, obesity rates continue to climb at alarming rates, 





1.3 Lipid Storage 
 
Obesity represents an expansion of the adipose tissue. Energy in the body can be stored as 
carbohydrates and protein, but the most efficient storage molecules are lipids. One gram of fatty acid 
produces 9 kcal of energy and does not require any water molecules for storage. By comparison, 
carbohydrates and proteins each produce 4 kcal per gram and must be stored with  additional water 
molecules. In a normal weight human male, roughly 80% of the body’s total energy storage is in lipids, 
capable of supplying the body with enough energy to last 30-40 days (43, 44).  Beta-oxidation is the 
primary way in which cells use fatty acids to generate ATP and meet energy needs (45). The first step 
beta-oxidation after a fatty acid is taken up by a cell,  is the formation of fatty acyl-CoA molecules in the 
cytoplasm.   Acyl-CoA molecules are then transported across the mitochondrial membrane where 
oxidation occurs. Once inside the mitochondrial matrix, the fatty acyl-CoA molecule is hydrolyzed in a 
stepwise fashion to yield acetyl-CoA, which enter the Krebs Cycle, generating reducing equivalents that 
are used to produce ATP (46).   
 
 Unlike free fatty acids (FFAs), which have detergent-like properties, the glycerol esters of fatty 
acids in the form of triacylglycerides (TAGs) remain hydrophobic at all pHs (47).   Acylglycerides are 
stored primarily in lipid droplets within cells.  The formation of lipid droplets is not entirely understood. The 
leading hypothesis is that TAG accumulate in the hydrophobic environment between the two layers of 
phospholipid membrane of the endoplasmic reticulum. As the lipid pocket grows, the outer layer of the 
phospholipid bilayer eventually buds off from the endoplasmic reticulum, producing an organelle 
surrounded by a phospholipid monolayer and filled with a core of neutral lipid (48, 49). This structure can 
then grow further through direct diffusion of FFAs or fusion with other lipid droplets or possibly through 
recently identified substructures (49) (50). The membrane of the lipid droplet also accumulates and is 
enriched with proteins that regulate TAG and cholesteryl ester trafficking and metabolism within the cell. 
 
The best-characterized lipid droplet-associated proteins are those of the perilipin family. The five 




cytoplasmic face of the lipid droplet membrane (51, 52). They have been implicated in regulating many 
different processes, including lipid metabolism, membrane stabilization and trafficking, endocytosis, 
exocytosis, and fusion of vesicles (53, 54). The expression patterns of the PLINs vary, with some being 
nearly ubiquitously expressed, e.g. PLIN4, while others have more limited expression, e.g. PLIN1 in 
adipocytes, PLIN2 in macrophages, hepatocytes. PLIN1, whose expression is largely limited to 
adipocytes, is the most studied and best characterized of the PLINs. One of its functions is as a negative 
regulator of lipolysis. In the absence of a lipolytic stimulus, it associates with another LD protein, CGI-58, 
preventing CGI-58 from activating LD associated lipases, including PNPLA2/ATGL (51, 52, 55).  Lipid 
droplets are found in nearly all cells providing temporary storage of TAG for subsequent use to meet 
energy needs or to be used as substrates in the creation of various important fatty acid-derived 
molecules. In adipocytes, lipid droplets also make up the majority of the volume of the cell.  
 
1.4 Adipocytes in Energy Storage 
 
There are several morphologically distinguishable types of adipose tissue which serve distinct 
functions. White adipose tissue is the primary site of TAG storage, bone marrow adipose tissue functions 
in hematopoiesis and brown/beige adipose tissue is thermogenic (56). The adipocyte is responsible for 
the major energy functions of adipose tissue, including storing TAG within its cell body. In white adipose 
tissue, adipocytes provide metabolic substrates, FFAs and glycerol, for other tissues during periods of 
energy deficit.  In humans, it has been estimated that adipocytes live for an average of 10 years and can 
change in size dramatically depending on their environment (57). Adipocytes in white adipose tissue 
typically contain one large unilocular lipid droplet. In obese subjects, this lipid droplet can be 20-fold larger 
in diameter than those in adipocytes of lean individuals, an increase in lipid volume of several thousand-
fold (58). Because of the dynamic energy needs of an organism, the size of the adipocyte lipid droplet can 
change rapidly, especially during times of fasting when a large fraction of adipocyte TAG can be 





Adipocytes provide energy substrates (FFAs and glycerol) to the rest of the body through the 
action of neutral lipases (59). During periods of negative energy balance, when caloric intake does not 
meet energy expenditure, hormonal (including high glucagon and norepinephrine, and low insulin 
concentrations) and neural signals (sympathetic activation) activate a lipolytic response in adipocytes (55, 
59, 60). These signals act, in part, through activation of protein kinase A which, through phosphorylation 
of PLIN molecules, lead to activation of neutral lipases that are associated with the LD membrane (61, 
62). Three lipases, adipocyte triglyceride lipase (PNPLA2/ATGL), hormone-sensitive lipase (LIPE/HSL) 
and monoacylglyeride lipase, act sequentially to hydrolyze a single fatty acid from a TAG molecule, 
yielding a glycerol backbone and three fatty acid residues (57, 60). FFAs then exit the cell, ultimately 
making their way into the circulation and providing energy to cells throughout the body (60, 63, 64).  
 
Once in the recipient cell, a FFA can be transported to the mitochondria to undergo beta-
oxidation, metabolized into other lipid species, or re-esterified into TAG for local storage. Esterification of 
FFAs with glycerol regenerates TAG that can once more be stored in a lipid droplet (65, 66). The re-
esterification process reverses hydrolysis, in a stepwise fashion, requiring the action of several 
acyltransferases. The best studied of these enzymes, the diglyceride acyltransferases (DGAT1, DGAT2), 
catalyze the terminal esterification of an acyl-fatty acid to diacylglycerol. Both enzymes are capable of 
catalyzing the reaction, and in their absence, TAG cannot be formed in mammals (67). While each has 
distinct cellular localization and tissue expression, there also is compensatory regulation that occurs when 
either is mutated.    
 
1.5 Delivery of Lipid and Lipoprotein Particles 
 
While adipocytes can convert glucose, via the generation of Acetyl-CoA, into FFA, most FFA in 
mammals has been thought to derive from circulating TAG carried in lipoprotein particles (68). TAGs are 
primarily transported in the hydrophilic bloodstream with lipoprotein particles. Apolipoproteins and lipid 
combine to form a complex family of lipoprotein particles that includes chylomicrons, chylomicron 




lipoprotein (LDL), and high-density lipoprotein (HDL). These particles have cores composed of cholesteryl 
esters, retinol esters, and TAGs in differing proportions. In addition to varying by lipid composition, each 
particle has a distinct size, density, and set of apolipoproteins associated with it. The TAG-rich VLDL and 
chylomicrons are synthesized by hepatocytes and intestinal epithelial cells, respectively, and like all other 
lipoprotein particles and lipid droplets, possess a phospholipid monolayer containing proteins (68).    
 
The packaging of dietary lipids into chylomicrons begins in the intestine, after orally consumed 
TAGs are hydrolyzed by luminal lipases which release FFAs that are in turn absorbed by enterocytes. 
Fatty acids and monoacylglycerides, once taken up by enterocytes, are transported to the endoplasmic 
reticulum (ER) (69). There, these substrates are converted into TAG by esterifying enzymes within the 
ER, including DGAT1/2. The apolipoprotein ApoB-48 is translated directly into the ER lumen and with the 
nascent lipoprotein particle forms a dense HDL-like pre-chylomicron, with high concentrations of 
phospholipids and free cholesterol. Microsomal triglyceride transfer protein then ferries and loads TAG 
into the pre-chylomicron particle.  
 
Once loaded with TAG, the prechylomicron leaves the ER and moves to the Golgi. The 
intracellular transport of the particle remains poorly defined, but it is hypothesized to occur by enclosing 
the prechylomicron in a membrane-bound vesicle derived from ER membrane: the prechylomicon 
transport vesicle (PCTV), averaging 250nm in diameter. Once released into the cytosol, the PCTV uses 
SNARE proteins to be targeted to the Golgi, where it fuses with the Golgi membrane, releasing the 
prechylomicron into the Golgi lumen. The prechylomicrons are further processed in the Golgi into mature 
chylomicrons before, again, being packaged in vesicles that fuse with the baso-lateral enterocyte plasma 
membrane, releasing the particles into the basal extracellular space (70, 71). Extracellular chylomicrons 
are taken up by the lymph and ultimately, via a thoracic duct, reach the circulation. Once in the 
circulation, chylomicrons receive ApoC-II and ApoE from HDL particles and now can efficiently deliver 





The enzyme lipoprotein lipase (LPL) is synthesized in the parenchymal and some immune cells of 
muscle, heart, and adipose tissue. After secretion, it translocates to endothelial cells where it is presented 
on the luminal side of capillary vessels. Via a mechanism that is incompletely understood, LPL interacts 
with chylomicrons and other TAG-containing particles in the circulation, and catalyzes the hydrolysis of 
TAG, allowing delivery of fatty acids to the underlying cells (72).  As TAG is depleted, the particle 
becomes smaller and becomes known as a chylomicron remnant (68, 73). These remnant particles are 
efficiently cleared by liver.  Apolipoprotein E (APOE) which is on the surface of the chylomicron is 
recognized by LDL-receptor and by Hepatic Lipase on the surface of the hepatocyte. The clathrin-coated 
pits surrounding LDL-receptor are activated upon binding, leading to the invagination of the hepatocyte 
membrane, taking up the remnant particle via receptor-mediated endocytosis. The intracellular vesicle 
fuses with acidic endocytic compartments where they undergo degradation (74).  The delivery of TAG via 
chylomicrons mirrors delivery via other lipoprotein particles (75). VLDL particles, which contain the 
apolipoprotein ApoB-100, develop in a very similar manner within the hepatocyte. VLDL TAG is derived 
from recycled lipoprotein particles or via de novo lipogenesis. 
 
1.6 The Complexity of White Adipose Tissue   
 
Although adipocytes are the defining cell-type in adipose tissue, being the most histologically 
distinct and the site of lipid storage, adipose tissue is heterogenous and complex. The non-adipocytes 
within adipose tissue, often referred to as the stromal vascular cells (SVCs), include endothelial cells, 
stem cells, fibroblasts, immune cells and pre-adipocytes. Each appears to play important roles in 
maintaining lipid storage and release function of fat. SVCs are known to mediate transport of energetic 
materials, respond to hormonal signals, and release hormonal signals themselves (76, 77). Among the 
immune cells, the largest population is the adipose tissue macrophage (ATM). 
 
Macrophages are professional phagocytes derived from the myeloid precursors. In most tissues 
there appear to be to populations of macrophages of varying proportions – one is derived from resident 




recruited to the tissue (78, 79). They are best known for their role in innate immune responses. 
Classically, in response to a local infection sentinel immune cells and damaged parenchymal cells 
elaborate pro-inflammatory cytokines, chemokines, and other signals that initiate an immune response. 
Macrophages serve many function in immune responses: 1) As sentinels, recognizing foreign pathogens 
and damaged cells via pattern recognition receptors  2) Phagocytosing debris, pathogens and dead and 
damaged cells 3) Presenting antigens to effector T cells that mediate adaptive immunity (80) (81, 82) (83-
85).   
 
1.7 Tissue Resident Macrophages and ATMs 
 
In addition to their role in innate immune responses, macrophages are present in tissues during 
normal, non-inflammatory functioning and have specialized, tissue-specific adaptive functions (86). For 
example, the tissue resident macrophages of the brain, microglia, perform synaptic stripping, a process 
by which microglia facilitate proper synaptic development during postnatal life (87-89). Another example 
are osteoclasts, the multinucleated tissue resident macrophage of bone, which resorb bone as part of the 
bone cycle required to maintain healthy bones (90-92).  A common feature to many of the tissue-specific 
functions of macrophages, is that they often degrade materials within a tissue, allowing the parenchymal 
cell to rebuild and improve function. 
 
The adaptive roles of adipose tissue macrophages are less well-defined. However, circumstantial 
evidence suggests they play a critical role in local lipid homeostasis (93). In the lean state, ATMs make 
up roughly 5-10% of the cells in white adipose tissue and contain measurable amounts of neutral lipid; in 
obese individuals the lipid content of ATMs increases several fold (94, 95). An analysis of ATMs in obese 
mice suggested that they play a degrative function, reminiscent of the roles played by osteoclasts and 
microglia (15, 96).  Obesity increases the number of ATMs so that they constitute as much as 50% of the 
cells in a fat depot and also increases the lysosomal function, and specifically the release of FFA in a 
lysosome-dependent manner.  More recently, ATMs have also been found to release lysosomes as part 





Lysosomal acid lipase (LIPA) is the one known enzyme that hydrolyzes TAG and other lipid 
esters in lysosomes and is highly expressed in ATMs (98, 99). In comparison, ATMs have relatively low 
expression of cytosolic, neutral lipases, i.e. PNPLA2/ATGL, HSL and monoacylglycerol lipase (MGL), and 
thereby, they depend on lysosomal lipases to hydrolyze lipid (100). The importance of this gene 
specifically in macrophages has been revealed over the last decade.  Hypomorphic or null alleles of LIPA 
manifest as cholesteryl ester storage disease (CESD) and Wolman Disease, respectively (101, 102). 
Although Wolman’s Disease is more severe and leads to early mortality, typically by age 2, whereas 
symptoms of CESD often do not become apparent until early adulthood, both are characterized by 
progressive loss of fat tissue and accumulation of lipid in the liver, spleen and small intestine.  This 
phenotype is replicated in mice deficient in LIPA. Like humans, these animals lose adipose tissue and 
develop massive hepatosteatosis and splenomegaly, but remarkably these defects are rescued by LIPA 
expression limited to macrophages, arguing for a role of macrophage lysosomal lipid catabolism being 
necessary to sustain adipose tissue and prevent ectopic TAG accumulation (103) (99).   
 
1.8 Inflammation and Obesity 
 
While the association of obesity with many co-morbidities including insulin resistance, 
dyslipidemia, more than a half dozen cancers, and dementia are well-documented, the mechanisms that 
underlie these associations remain poorly defined. One compelling model focuses on the longstanding 
observations that measures of inflammation increase with obesity and incidence of its complications 
(104). For example, in both animal models and humans, measures of inflammation in adipose tissue 
correlate strongly with one’s risk for developing insulin resistance, a relationship that is even stronger 
than the relationship between insulin resistance risk and BMI (105, 106). A causative role for inflammation 
is supported by many preclinical and genetic studies in rodents, in which treatments or genetic variants 
that increase inflammation worsen obesity-associated insulin resistance and those that reduce 




stresses”, mediated, in part, by immune cells, activate inflammatory signaling in energetic cells, such as 
skeletal muscle myoblasts, to impair normal glucose and lipid metabolism.    
 
While the data from rodent models are compelling, there are some problems with this model. 
Genome-wide association studies (GWAS) that identify variants associated with insulin resistance, have 
identified very few inflammatory or immune genes (109, 110).  In many other disorders where 
inflammation and immune dysfunction are clearly causative, e.g. inflammatory bowel disease, type 1 
diabetes, GWAS have identified variants in many inflammatory genes. If inflammation were central to the 
development of insulin resistance, one would similarly predict evidence that variants in an inflammatory 
gene contribute to the risk for developing the disorder.  A second challenge to the model is that anti-
inflammatory therapies developed to treat autoimmune disorders, and that target the same molecules 
implicated in rodent models of inflammation, have not been associated improved insulin sensitivity (111). 
The recently completed large CANTOS trial, which found some evidence for reduced cardiovascular 
disease upon treatment with an anti-Il1b molecule, did not reduce insulin resistance or the development 
of type 2 diabetes (112). Another paradox is that several mouse models have now been developed that 
disassociate inflammation, including adipose tissue inflammation, and insulin resistance. For example, 
mice fed a high-fat diet at thermoneutrality develop adipose tissue inflammation without any effect on 
systemic insulin signaling (113). 
 
1.9 Ectopic Lipid Deposition and Obesity 
 
In addition to measures of inflammation, epidemiological studies have found that complications of 
obesity are also strongly associated with deposition of lipids in non-adipocytes (114). Triglyceride storage 
in ectopic (non-adipose tissue) depots is a common feature of obesity and a strong predictor of the 
development of for T2DM, atherosclerosis, and fatty liver disease (115). What leads to TAG being stored 
in these tissues is unknown, but it seems to be tied to adipose tissue dysfunction, as it is often 
accompanied by stress signaling in the adipose tissue, including endoplasmic reticulum stress, unfolded 





The proposed mechanisms through which ectopic lipid contributes to insulin resistance in key 
metabolic tissues involve metabolites of TAG and other lipids activating either activating signaling 
pathways in a lipid species-specific fashion or via more general stress responses. Obesity does lead to 
the accumulation of long-chain acyl-CoA, diacylglycerol (DAG), and ceramides in tissues including 
skeletal and cardiac muscle, liver and pancreas (1). In the case of diacylglycerol, it has been proposed 
that DAG activates atypical protein kinase C isoforms which will phosphorylate insulin receptor substrates 
on serine residues that inhibit insulin signaling (117-119). Others have suggested that a broader of effect 
of lipids on cells is to induce ER stress responses that similarly activate kinases and impair insulin 
signaling. However, compelling data from rodent models in support of these mechanisms have not 
successfully translated into therapeutic strategies in people. Furthermore, GWAS studies of insulin 
resistance and other obesity complications have also not uncovered a set of variants consistent with 
signaling implicated in murine studies (109, 110). And like the exceptions to the association of 
inflammation with obesity and its complications, there are examples of dissociation of ectopic lipid 
accumulation with obesity complications that are not explained by the current models. For example, well 
trained athletes accumulate triglyceride in muscle but have increased rather than impaired insulin 
sensitivity (120).  
 
1.10 ATMs and Obesity’s Co-Morbidities 
 
ATMs lie at the intersection of two leading models for the pathogenesis of obesity-associated 
disorders, including insulin resistance. Their contribution to adipose tissue inflammation is direct, but data 
also implicate ATM dysfunction in ectopic lipid deposition. Disrupting the ability of ATMs to handle lipid is 
associated with TAG being stored outside of the adipose tissue. As noted above loss of LIPA activity 
specifically in macrophages is sufficient to cause massive TAG accumulation in the liver and spleen (99). 
Additionally, macrophages can be conditionally depleted using Macrophage Fas-Induced Apoptosis 
(MAFIA) transgenic mouse model. When macrophages are depleted in mice being fed a high fat diet, 
there is a 30% reduction in adipose tissue mass, while liver and gut fat content increases, providing 
further evidence that ATMs are essential for maintaining adipose tissue lipid homeostasis and preventing 







 Exosomes are extracellular vesicles (EVs) that are secreted by all eukaryotic cells so far studied 
(123, 124).  Like all EVs, they are particles delimited by a single phospholipid bilayer membrane and filled 
with an aqueous interior. The components are derived from the cell that secretes it: the membrane 
derived from the endocytic multivesicular bodies, and the contents derived from the cytoplasm (125). 
Exosomal biogenesis begins with the inward budding of a cell’s plasma membrane. ESCRT machinery 
facilitates the invagination of the limiting membrane into the interior of the cell, creating an intraluminal 
endosomal vesicle (ILV), filled with extracellular contents (125-127). Through endosomal maturation an 
ILV is enriched with certain lipid species and membrane-associated proteins, including tetraspanins, e.g. 
CD63. The contents of the eventual exosome are trafficked to the ILV membrane. These contents are 
enveloped by the membrane as it once again invaginates and buds inward to the interior of the vesicle. 
This process repeats until the intraluminal vesicle matures into a multivesicular body (MVB), containing 
many proto-exosomes. At this point, depending on the cell’s needs and environmental signally, the MVB 
can fuse with the lysosome to be degraded, and recycle its materials, or it can be transported to the 
plasma membrane for exosomal secretion (132, 133).  MVBs that fuse directly with the cell’s plasma 
membrane, do so through a process that requires Rab GTPases and the SNARE complex (128). This 
releases both the exosomes and the extracellular contents that were taken up during ILV formation.  
 
 Exosomes range in diameter from 50 nm to 200 nm, making their average size larger than LDL 
particles (22nm in diameter), but still an order of magnitude smaller than the smallest cells. There is a lack 
of consensus regarding the classification of extracellular vesicle subtypes into distinct groups. Some of 
these classifications are based on size, others on mechanisms of biogenesis, or others on differences in 
function. For the purposes of this work, the term “exosome” is being used as a blanket term for 
extracellular vesicles of ~70-200 nm in size not derived from apoptotic cells. 
 
Almost all cell types have been shown to release exosomes, including animal, plant, and 




function in intracellular communication. By carrying signaling molecules in their natural cytoplasmic 
environment, including RNAs, protein, and lipids they can have direct effects on the recipient cell once the 
interior of the exosome either fuses with a recipient cell or is taken up via a phagocytic process. While 
exosomes and other extracellular vesicles can act in a local fashion, their sturdy phospholipid bilayer 
enables them to travel great distances within the body for extended periods, while protecting their 
contents from degradation.  
 
  While exosome biogenesis is rather well-studied, the mechanisms of exosome uptake a 
comparatively much less understood. The mechanisms of exosome targeting and adhesion are also a 
topic of debate in the field. Many reports describe exosomes that are taken up by only specific types of 
cells, depending on the origin of the exosome. How this phenomenon is carried out is an open question 
(129).  Exosomes released from immune cells have been shown to express integrins such as ICAM-1, 
CD18, CD29, and CD51 that are able to bind tightly to integrin receptors on recipient cells. Tetraspanins, 
a family of highly conserved membrane proteins that play a role in adhesion, motility, and signal 
transduction are expressed on all exosomes. Some of these include CD9, CD63, CD53, CD81, and 
CD82, although the specific tetraspanins on individual exosome populations vary. The variation in 
tetraspanins has been postulated to modulate both the content that is partitioned into a given exosome 
and alter the target cell which takes up or fuses with an exosome.   
 
 Once the exosome has arrived at the recipient cell it has several different ways of mediating its 
effects. Some exosomes are able to induce changes in recipient cells, through extracellular contact, 
interacting with receptors on the cell’s surface without being taken up (130). Exosomes are capable of 
fusing directly with the plasma membrane of recipient cells, through a mechanism that is not very well 
studied, immediately introducing the exosomal contents into the recipient cell. This allows mRNAs, 
miRNAs and proteins to function directly within the target cell (131).  
 
 The most commonly reported means of exosome uptake occurs through the endosomal pathway. 




exosomal surface interact with receptors in cholesterol and sphingolipid rich rafts on the surface of the 
recipient cell. This stimulates a clathrin-dependent endocytosis that utilizes caveolins to coat the 
membrane, inducing an invagination of the membrane into an intracellular vesicle (131). Non-receptor-
meditated endocytosis, including phagocytosis and macropinocytosis are also reported to take up 
exosomes en mass. This process involves the outward protrusion of the plasma membrane, driven by 
actin filaments, that surround and endocytose extracellular fluid and particles contained within, a process 
dependent on PI3K and dynamin-2 (132). Once exosomes enter the endocytic pathway, sorting takes 
place by which exosomal proteins and membrane lipids can be trafficked back to the plasma membrane 
or to the late endosome and lysosomes (133).   Over the last twenty five years the identification of pattern 
recognition receptors in endocytic compartments and nutrient sensing apparatus associated with the 
lysosome argues that exosomes in this pathway can trigger signaling responses that are dependent on 
the contents of the exosomes (134).  
 
1.12 Adipose Tissue-Derived Exosomes  
 
 The study of adipose tissue-derived exosomes is still in its infancy, but already, they have been 
shown to have many important local and systemic effects, with some groups claiming that >60% of the 
circulating RNA is derived from adipocyte exosomes (135). There are multiple reports of adipose tissue-
derived exosomes having systemic effects on key metabolic tissues (136). For example, one study found 
that, in mice, adipocyte-derived exosomes traffic to the liver where they are taken up by hepatocytes.  In 
the hepatocytes, exosomal microRNAs directly inhibit FGF21 expression and improve glucose 
homeostasis in obese mice (135).  More recently, exosomes from endothelial cells in adipose tissue have 
been shown to transfer functional caveolin 1 protein to adipocytes, thereby regulating adipocyte function 
(137). Several groups have suggested that ATM-derived exosomes act to modulate systemic metabolism 
either by locally regulating adipocytes to alter adipokine secretion or by direct inflammatory effects on key 
metabolic tissues, including the liver and pancreas (138). Although many of these studies await 
replication and confirmation, it seems clear that adipose tissue plays a large role in exosomal signaling at 
large, and that once the biology of exosomes is more clearly elucidated, adipose tissue derived 
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Adipose tissue contains many cell types including adipocytes, endothelial, mesenchymal, stem, 
and immune cells. All have distinct roles, some of which are clear, while others are still emerging.  In 
white adipose tissue, adipocytes contain large unilocular lipid droplets composed of triacylglycerides 
(TAGs) and other neutral lipids. These TAGs serve as the major long-term energy reserves for the body 
in mammals (1). During times of negative energy balance, starvation signals are sent to the adipose 
tissue to mobilize these energy reserves. Our current understanding is that this occurs through the 
activation of cytoplasmic lipases in the adipocyte, including adipose tissue triglyceride lipase 
(ATGL/PNPLA2), hormone sensitive lipase HSL, and monoglyceride lipase (MGL) (2, 3). These enzymes 
sequentially hydrolyze triglyceride within lipid droplets, cleaving the ester bonds of the glycerol backbone 
and releasing three free fatty acids per TG molecule (4). The free fatty acids are released from the cell, in 
a process that still remains poorly defined, and enter the circulation where they can be taken up by the 
cells as metabolic substrates (5). 
 
Adipose tissue macrophages (ATMs) are present in the adipose tissue and contain amounts of 
neutral lipid visible by light microscopy (6, 7). Both ATM number and lipid content increase in obese 
animals and individuals (8, 9). It had been assumed that ATM lipid stores originate from adipocyte-
released free fatty acid (FFA).  The accepted model postulated that FFAs are taken up by the 
macrophage, re-esterified by diglyceride acyltransferases (DGAT1 & DGAT2), and stored in intracellular 
lipid droplets (Figure 2.1). This model explained that the increased lipid content of ATMs that is observed 






Figure 2.1. Prevailing model of neutral lipid accumulation in adipose tissue macrophages. 
 
Aggregates of neutral lipid within cells are typically stored in lipid droplets, organelles whose 
perimeter is defined by a phospholipid monolayer, and that serves as the transition barrier between the 
hydrophobic lipid core and the hydrophilic cytoplasm (12, 13). This lipid droplet monolayer contains 
proteins required for droplet formation, lipid flux into and out of the droplet, and signaling (14, 15).  Over 
the last decade, studies also revealed that lipid droplets, or portions of lipid droplets, can undergo 
autophagy, providing a mechanism to deliver lipid to the lysosome for hydrolysis by acid lipase(s) (2, 16, 
17). Unexpectedly, previous studies had revealed that lipid in ATMs underwent lysosomal hydrolysis by a 
mechanism independent of classical macroautophagy (18). This suggested that visible, aggregated 
neutral lipid in ATMs might not be contained within lipid droplets.   
 
Among the most abundant lipid droplet-associated proteins are the perilipin (PLIN) family 
proteins, a family of molecules that in cell-specific fashions are key regulators of lipase activity (19-21). 
They are commonly used as immunohistochemical markers of lipid droplets, and the predominant PLIN-
protein in macrophages is perilipin-2 (PLIN2)(20, 22). To further characterize the neutral lipid storage 
within ATMs we used confocal microscopy of whole adipose tissue. Adipose tissue from obese mice was 




fluorescent dye used to visualize neutral lipid, 2) DAPI, a fluorescent dye used to stain nucleic acids and 
to mark nuclei, and antibodies against 3) F4/80, a marker found in macrophage plasma membrane, and 
4) PLIN2, a protein on classical macrophage lipid droplet membranes. Despite many examples of 
PLIN2+/BODIPY+ lipid droplets within the ATMs, the majority of BODIPY staining within F4/80+ cells was 
not associated with PLIN2 (Figure 2.2), indicating that neutral lipid within ATMs is either not stored in lipid 
droplets, or that a subpopulation of lipid droplets in ATMs lack PLIN2. 
 
In order to investigate the lipid content in ATMs and its delivery from adipocytes, we moved to an 
in vitro system.  Previously, it had been shown that culturing bone marrow derived myeloid precursor cells 
with colony stimulating factor-1 (CSF1/MCSF) in the presence of adipose tissue, leads to the 
differentiation of precursors into macrophage cells that accumulate lipid and are ATM-like (18, 23). The 
technique we used to generate ATM-like cells employed  bone marrow from femurs of young mice that 
were co-cultured with perigonadal adipose tissue (PGAT) from adult mice.  We have dubbed these cells 
bone marrow adipose tissue macrophages (BM-ATMs) to distinguish them from bone marrow cells 
differentiated solely in the presence of CSF1 (BMDMs). This process induces the cells to assume many of 
the characteristics of primary ATMs, including neutral lipid accumulation, multinuclear formation, a 
transcriptional profile typical of ATMs, lysosome biogenesis, and lipid catabolism, as described previously 
(18, 23). 
 
Because BM-ATMs grow in a monolayer, we used transmission electron microscopy to study 
their cellular ultrastructure.  As a positive control, we used foam cells generated in vitro. Briefly, treating 
BMDMs with acetylated-LDL leads to formation of  in vitro foam cells – similar to macrophages seen in 
atherosclerotic plaques.  It has previously been shown that lipid in in vitro foam cells is stored in lipid 
droplets (monolayer membrane) and undergoes hydrolysis, in part, via lipophagy (Figure 2.3, right [Ambar 
Grijalva]). In contrast, in BM-ATMs we could detect some lipid droplets (monolayer membrane), but most 
of the lipid seemed to be stored in distinct lipid vesicles surrounded by a bilayer membrane (Figure 2.3, 






Figure 2.2. ATM lipid stores not associated with lipid droplet proteins. Confocal microscopy images 
of whole PGAT from Lepob/ob mice, immunostained with antibodies against perilipin 2 (red) and F4/80 
(blue) and incubated with DNA fluorescent stain 4′,6-diamidino-2-phenylindole (DAPI) (white) and neutral 
lipid fluorescent stain boron-dipyrromethene (BODIPY) (green). Orange arrow highlights lipid 
accumulation within ATM. Scale bars, 10 mm. 
 
 
Figure 2.3. BM-ATM lipid stored in intracellular vesicles. Electron microscopy images of BM-ATMs 
(left) and bone marrow–derived foam cells (right). Arrows highlight lipid vesicles and lipid-rich 




Lipid droplets are formed through the esterification of FFA, but given the distinct structures in 
which lipid resides in BM-ATMs, we were prompted to determine whether lipid released by adipocytes 
requires lipolysis of TG or is distributed through an alternative mechanism. Adipocyte-specific 
ATGL/PNPLA2 deficient animals do not tolerate fasting but tend to have large amounts of lipid in ATMs 
(24). To determine the relative contribution of lipolytic free fatty acid to ATM lipid accumulation, WT 
BMDMs were co-cultured with WT PGAT or with PGAT from adipocyte-specific ATGL/PNPLA2 deficient 
mice. Using confocal microscopy, we saw that BMDMs co-cultured with WT PGAT had the expected 
accumulation of neutral lipid (Figure 2.4, middle [Ambar Grijalva]). Surprisingly, however, PGAT from 
adipocyte-specific ATGL/PNPLA2 deficient mice was just as effective at inducing BMDM lipid 
accumulation as WT PGAT (Figure 2.4, bottom [Ambar Grijalva]). 
 
The existence of an alternative mechanism was confirmed using pharmacological inhibitors of 
lipolysis. Atglistatin, an ATGL/PNPLA2 inhibitor, was able to effectively decrease the amount of free fatty 
acid (FFA) released from WT PGAT explants (Figure 2.5). But whether conditioned medium from these 
explants or control-treated explants were added to WT BMDM cultures, macrophages accumulated 
equivalent amounts of TG (Figure 2.6). The same phenomenon can be seen when treating explants with 
lipolytic inhibitors known to affect hormone sensitive lipase, as well (Figure 2.7). This demonstrates that 









Figure 2.4. PGAT from ATGL deficient animals transfers lipid to BMDMs when co-cultured. 
Confocal microscopy images of BMDMs (top), BM-ATMs differentiated in the presence of adipose tissue 
(middle), and BM-ATMs differentiated in the presence of Atgl/Pnpla2-deficient adipose tissue (bottom), 
immunostained with antibodies against F4/80 (blue), as well as DNA fluorescent stain DAPI (white) and 
neutral lipid fluorescent stain BODIPY (green). Scale bars, 10 mm. 
 
 
Figure 2.5. Atglistatin treatment decreases FFA release from PGAT explants. Free  fatty  acid  
content of  PGAT  conditioned  medium  cultured  with  or  without Atglistatin for 16 hours per gram per 






Figure 2.6. Atglistatin treatment does not reduce neutral lipid transfer to BMDMs. Triglyceride 
content of BMDMs (untreated) or treated with medium-containing 50µM Atglistatin, BM-ATM differentiated 
with conditioned medium of wild-type (WT) PGAT or with conditioned medium WT PGAT treated with 50 
µM Atglistatin. One-way analysis of variance (ANOVA); n = 6; ***P < 0.001. Error bars represent standard 
deviation (SD). 
 
Figure 2.7. HSL inhibition does not reduce neutral lipid transfer to BMDMs. Triglyceride content of 
BMDMs (untreated) or treated with medium-containing 5µM CAY10499, BM-ATM differentiated with 
conditioned medium of wild-type (WT) PGAT or with conditioned medium WT PGAT treated with 5 µM 




In search of this alternative mode of lipid release from adipocytes we examined the interior 
structure of primary mouse adipocytes using electron microscopy. These micorgraphs reveal the 
expected large unilocular lipid droplet in each cell and a thin rim of cytoplasm.  However, they also 
revealed smaller, invaginated, lipid-filled bodies in the cytoplasm (Figure 2.8). The position and structure 
of these bodies were consistent with smaller lipid droplets either fusing with or budding off of the central 
lipid droplet. Also visible were nearby structures consistent with multivesicular endosomes (25-27). A 
major function of multivesicular endosomes is as an intermediary step in the release of extracellular 
vesicles, including exosomes(28-30). 
 
Exosomes are small cellular-derived vesicles ranging in diameter from 50nm to 200nm (31). 
Exosomes are released by most cell types and can function in intercellular communication (32, 33). 
These vesicles are bound by phospholipid bilayers and contain protein, mRNA, miRNA, and lipid species 
from their cellular parent (30, 34-38). Given these observations, we hypothesized that lipid transfer from 
adipocytes to BMDMs occurs, in part, via exosomes. To begin to test this, we examined conditioned 
media from mouse PGAT explants, cultured without serum with electron microscopy. These micrographs 
revealed a high concentration of extracellular vesicular particles ranging in diameter from 50 to 100 nm, 









Figure 2.8. Adipocytes contain small, invaginated lipid structures in their cytoplasm. Electron 
microscopy image of whole, fixed adipose tissue.  Arrows highlight the adipocyte plasma membrane and 
the budding- like structures of the central lipid droplet (orange and blue arrows, respectively), and the red 
outline indicates a multivesicular endosome-like structure. Scale bar, 200 nm. 
 
Figure 2.9. PGAT conditioned medium contains extracellular vesicles in the size range of 
exosomes. Electron microscopy image of vesicles collected from adipose tissue–conditioned medium. 




Because these adipose tissue-derived exosomes (AdExos), were expected to contain large 
amounts of neutral lipid, this presented a new challenge as the gold standard for exosome purification is 
separating extracellular materials by density using ultracentrifugation. As the high lipid content of AdExos 
would likely affect their density, such that they would no longer be found at expected exosomal densities, 
we set out to isolate these exosomes using a different technique. Using a series of gel fractionation 
columns and filtration, we were able to achieve a high level of purity in our exosome samples, as 
determined by Nanoparticle Tracking Analysis (NTA), separating extracellular materials strictly by size 
and not by density (Figure 2.10). 
 
As a secondary method of verification for the protocol, we took advantage of the structure of the 
exosome, namely its phospholipid bilayer membrane, which allowed for labeling using fluorescent dyes, 
like PKH26 and PKH67 which intercalate within lipid bilayers  (39, 40). AdExos were incubated with 
PKH26 and then isolated using the size-exclusion method. Fractions were collected as they came off of 
the final column. Each fraction’s PKH26 fluorescence was measured and each fraction was analyzed 
using NTA. The fractions that contained particles consistent with exosomes were the same fractions that 
contained the PKH26 label (Figure 2.10). This is in contrast to exosomes that were incubated with bovine 
serum albumin (BSA) before being labeled, as the BSA-bound PKH26 came off of the column in later 











Figure 2.10. Exosomes elute with fluorescent label. PKH26  fluorescence  (left  y-axis)  and  exosome  
concentration,  as  determined  by Nanoparticle  Tracking  Analysis  (right  y-axis),  of  gel  filtration  
column  fractions  (n  =  3). 
 
Figure 2.11. Exosomes do not elute with BSA. Exosomes were co-labeled with BSA before being 
added to gel filtration column. PKH26  fluorescence  (left  y-axis)  and  exosome  concentration,  as  





After establishing a suitable protocol for purifying AdExos, we set out to characterize them. The 
AdExos were found to range in diameter from 50nm – 200nm as determined using NTA on two different 
instruments: the Nanosight (Supplemental Figure 1.1, Supplemental Figure 1.2) and the Viewsizer 3000 
(Supplemental Figure 1.3, Supplemental Figure 1.4). The measurement of size, distribution and number 
of AdExos obtained by the two systems were very similar.  (Figure 2.12, Figure 2.13). We found that 
PGAT from lean 10-week-old mice released ~1.3x1011 particles per gram of tissue each hour (Figure 
2.14). In addition, the rate of AdExo release was stable from hour to hour within a 12-hour culture period 
(Figure 2.15). The exosome release rate from PGAT is relatively high when compared to rates reported 
for other tissues that have been studied using the same technique (41-43).  
 
Exosomes, as a class of extracellular vesicle, contain proteins that have been implicated in their 
biogenesis and function, including CD63, HSP70 and CD9 (32, 37). Using antibodies against these 
proteins, we were able to confirm their presence in our AdExo samples via western blot (Figure 2.16). Our 
hypothesis argues that AdExos also contain proteins typically found in adipocytes. Among the proteins 
most abundant in and relatively specific to adipocytes are caveolin 1 (CAV1), fatty acid binding protein 4 
(FABP4), and adipocyte lipid droplet membrane-associated proteins, including ATGL/PNPLA2 and 
PLIN1.  Indeed, each of these are detectable by western blot in AdExos (Figure 2.17, Figure 2.18). 
Notably, AdExos do not contain cytochrome c oxidase subunit 4 (COXIV) or lamin b1 (LAMINB1), 
consistent with these exosomes not containing mitochondrial or nuclear debris (Figure 2.17). PGAT from 
adipocyte-specific ATGL/PNPLA2 deficient animals still secrete AdExos and these AdExos still contain 
the same proteins, except that ATGL/PNPLA2 can no longer be found in the exosomes, indicating that 








Figure 2.12. Majority of AdExos in 50nm – 200nm diameter range. Nanosight Nanoparticle Tracking 
Analysis histogram of purified adipose tissue-derived exosomes, depicting particle diameter and the 
number of particles at each diameter released by 1 g of lean adipose tissue per hour. 
 
Figure 2.13. Majority of AdExos in 50nm – 200nm diameter range. Viewsizer 3000 Nanoparticle 
Tracking Analysis histogram of purified adipose tissue-derived exosomes, depicting particle diameter and 





Figure 2.14. PGAT releases ~1.3x1011 AdExos per gram of tissue per hour. Quantification of 
exosome released by adipose tissue per gram per hour from adipose tissue from lean mice. n = 8; Error 
bars represent SD. 
 
 
Figure 2.15. AdExo release rate is stable over a 12-hour period. Exosome  release  from  obese  
PGAT  expressed  per  gram  of  tissue,  as  measured  by Nanoparticle  Tracking  Analysis.  Conditioned  






Figure 2.16. AdExos contain canonical exosome proteins. Western blots of exosomal protein isolated 
from adipose tissue-conditioned media (AdExos) and conditioned media content smaller than 100 kD 
(filtrate). Blots were probed using antibodies against CD63, HSP70, and CD9. 
 
Figure 2.17. AdExos contain adipocyte proteins. Western blots of exosomal protein isolated from 
adipose tissue–conditioned media (AdExos), conditioned media content smaller than 100 kD (Filtrate), 






Figure 2.18. AdExos contain adipocyte lipid droplet-associated protein PLIN1. Western  blots  of  
exosomal  protein  isolated  from  adipose  tissue  conditioned  media  (AdExos),  whole  perigonadal  
adipose  tissue  (PGAT),  and  whole  liver  lysate  (Liver). Blots were probed using antibodies against 
PLIN1 and bActin. 
 
 
Figure 2.19. AdExos from adipocyte-specific ATGL deficient animals do not contain ATGL. 
Western  blots  of  AdExo  protein  isolated  from  lean,  obese  (Lepob/ob), and  adipocyte-specific ATGL-





The electron micrographs of adipose tissue (Figure 2.8) and presence of lipid droplet-associated 
proteins suggest that the AdExos have an unusual structure and may maintain an intact lipid droplet 
membrane surrounded by a plasma/endosomal membrane derived bilayer. If so, the topology would 
predict that CD63 would be found on the exterior surface of the AdExo bilayer while lipid droplet-
associated proteins would be contained within the AdExos and not exposed to the exterior (Figure 2.20). 
To determine whether these proteins were localized as expected, purified AdExos were exposed to a very 
low concentration of proteinase K, an enzyme that hydrolyses amid peptide bonds, but cannot cross lipid 
bilayers. When AdExos are exposed to proteinase K, western blot with antibodies against ATGL/PNPLA2 
and the extracellular domain of CD63 revealed that CD63 is rapidly degraded while the ATGL/PNPLA2 is 
stable (Figure 2.21). However, if the AdExos are first exposed to a non-ionic detergent (Triton X-100), 
which disrupts membrane structures before proteinase treatment, both ATGL/PNPLA2 and CD63 are 
degraded (Figure 2.21). These experiments confirm that CD63 localizes to the exterior plasma membrane 



















Figure 2.21. AdExo ATGL is protected from Proteinase K degradation. Western blots of protein 
extracted from purified exosomes that were untreated, treated with 100 mg/ml proteinase K, treated with 









AdExos were released in high rate and contained exosomal and adipocyte lipid droplet proteins. 
We next tested whether they contained lipid and were possibly the vehicle for lipid transfer to BMDMs. 
Using enzymatic assay on PGAT conditioned medium and AdExo fractions purified from that conditioned 
medium, we found that AdExos contain very little FFA as compared to the total FFA released from the 
tissue (Figure 2.22). However, AdExos contain high concentrations of acylglyceride and a high fraction of 
the total amount of acylglyceride released from the tissue (Figure 2.23). Lean PGAT releases nearly one 
µmol of acylglyceride per gram of tissue in AdExos every hour. This is 0.04% of the total acylglyceride 
content of the tissue being released in exosomes every hour (Figure 2.24). Although these rates are 
dwarfed by the release of lipid during maximally activated lipolysis, a steady release rate implies the 
complete turnover of lipid within adipocytes by exosomes, every 104 days in lean animals(44-47). As 
discussed previously, treating PGAT explants with inhibitors of lipolysis is able to acutely reduce FFA 
release from the tissue (Figure 2.6). This treatment, however, has no effect on exosome release rate and 
the lipid content of the AdExos (Figure 2.25, Figure 2.26). 
 
 
Figure 2.22. AdExos contain little free fatty acid. Free fatty acid content of PGAT conditioned medium 
and exosomes isolated from that medium after a 16-hour culture, expressed per mg of tissue per hour 






Figure 2.23. AdExos contain high levels of acylglyceride. Acylglyceride content of PGAT conditioned 
medium depleted of AdExos and exosomes isolated from that medium after a 16-hour culture, expressed 
per mg of tissue per hour. Unpaired two-tailed t test; n = 8; ***P < 0.001. Error bars represent SD. 
 
Figure 2.24. AdExo acylglyceride content by percent. Acylglyceride content of conditioned medium 
depleted of AdExos and purified adipocyte-derived exosomes, expressed as a percentage of the 







Figure 2.25. Atglistatin treatment does not affect AdExo release rate. Quantification of total particle 
count via NTA released by PGAT, treated with or without Atglistatin for 16 hours per gram per hour (n = 
6). 
 
Figure 2.26. Atglistatin treatment does not affect the amount of acylglyceride released within 
AdExos. The rate of release of acylglyceride associated with AdExos isolated from adipose tissue 











































To further characterize the lipid content of these vesicles, we performed targeted lipidomics via 
mass spectroscopy on purified AdExos. Given the AdExos’ size and that they likely contain both a 
phospholipid bilayer and a phospholipid monolayer, we expected that on a molar ratio, membrane-
associated lipids would be the dominant lipid species. Indeed, this turned out to be the case, with 
phospholipids and free cholesterol making up the majority of the lipid contained within the vesicles (Figure 
2.27). The exosomes also contained stoichiometrically large amounts of acylglyceride, that were roughly 
evenly distributed between triacylglycerides (TAGs) and monoacylglycerides (MAGs) (Figure 2.27). On 
the basis of physical chemical properties and the concentration of TAGs and MAGs, we would predict a 
volume of 2.6x10-21 m3 of acylglyceride per exosome. This is roughly consistent with the predicted internal 







Figure 2.27. AdExo targeted lipidomics. Targeted lipidomics of adipocyte-derived exosomes isolated 












Based on these data, a model of AdExo structure emerged in which they range in diameter from 
50nm – 200nm.  These data are also consistent with AdExos being surrounded by a phospholipid bilayer 
membrane derived from the invagination of the adipocyte plasma membrane. This membrane contains 
adipocyte membrane proteins, such as CAV1, and exosome-associated proteins, such as CD63. Within 
the AdExos we predicted there would be what is the equivalent of a miniature adipocyte lipid droplet. This 
structure has a core of neutral lipid, made up of TAGs and MAGs, and a significant amount of cholesteryl 
esters. The neutral acylglyceride core is surrounded by a phospholipid monolayer, rich in 
phosphatidylcholines and free cholesterol. Associated with this monolayer are adipocyte lipid droplet 
membrane-associated proteins, including ATGL/PNPLA2 and PLIN1 (Figure 2.28).     
 
 
Figure 2.28. Graphical representation of adipocyte lipid droplet structure (left) and hypothesized 
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CHAPTER 3:INVESTIGATING THE EFFECTS OF ADIPOSE TISSUE-DERIVED EXOSOMES ON THE 




Macrophages are key mediators of the innate immune response. Myeloid in origin, they act as 
sentinels recognizing damage to tissue and foreign pathogens via pattern recognition receptors. In 
response, they expand their numbers, orchestrate the response of other immune cells and clear debris 
and pathogens via phagocytosis. They expand their numbers locally either by expansion of tissue 
resident cells or by differentiation of recruited monocytes into macrophages (1, 2).  In a pathogen or 
injury-specific manner, macrophages elaborate cytokines, chemokines, and bioactive lipids to recruit and 
activate other immune cells. A successful immune response typically requires the coordinated action of 
multiple immune cells, that in a classic bacterial infection includes the initial recruitment of neutrophils, 
followed by a wave of macrophages and dendritic cells, that then can present antigen to T-cells. 
Throughout the immune response, macrophages clear debris, apoptotic or damaged cells and pathogens 
through phagocytosis (4-6). Macrophages are fit with the tools of professional phagocytes, capable of 
invaginating their cell membranes to envelop and degrade large amounts of material via phagocytosis (7-
9). 
 
In the absence of infection or tissue damage, most organs contain a population of resident 
macrophages that exist in a non-inflammatory state (10).  For many of these tissue resident macrophages 
investigators have identified tissue-specific adaptive functions (11). For example, the microglia are the 
tissue resident macrophage of the brain and these cells are capable of performing synaptic stripping (12-
15), and the osteoclasts, multinucleated macrophages of the bone, are specialized in mineralized bone 
resorption (16, 17). Both these processes are required to maintain healthy tissue.  
 
Adipose tissue has its own tissue resident macrophage population, dubbed adipose tissue 
macrophages (ATMs). ATMs contain varying amounts of neutral lipid but can be so lipid-laden that they 
float in aqueous buffers and resist sedimentation when centrifuged. They also possess distinct 




populations (18-22). The efforts that led to the identification of AdExos described in the previous chapter 
were originally focused on the lipid handling by ATMs. We discovered that they accounted for the majority 
of TAG in the conditioned medium from adipose tissue and are therefore, a potential source of lipid found 
in ATMs. In this chapter we sought to determine whether macrophages do take up AdExos and whether 
they alter the lipid content and profile of cells that do.     
 
AdExos are taken up by ATMs 
 
As discussed in the previous chapter AdExos are surrounded by a phospholipid bilayer that is 
derived from the adipocyte plasma membrane. Because of this membrane, dyes such as PKH26 and 
PKH67 which intercalate into phospholipid bilayers can be used to label AdExos, allowing for tracing 
studies. To test whether ATMs in vivo take up AdExos, isolated AdExos were labeled with PKH26 and 
injected into PGAT. Using whole tissue confocal microscopy, we could follow the fate of the AdExos and 
identify which cells take them up.  From whole-mount images it is clear that the PKH26 signal 
concentrates in cells that are not adipocytes (Supplemental Figure 3.1). If this tissue is counterstained 
with an antibody against F4/80, a macrophage marker, it becomes clear that the PKH26 exosome uptake 
signal and the F4/80 signal co-localize, indicating that the exosomes are being taken up by ATMs in the 
PGAT (Figure 3.1). 
 
To further investigate the target cells within the PGAT, the injected tissue was treated with a 
collagenase allowing separation of adipocyte and non-adipocyte, stromal vascular cell (SVC) fractions. 
The cells in each fraction were lysed and measured for PKH26 fluorescence using a fluorescence 
spectrophotometer. Cells from PGAT which was injected with PBS instead of PKH26-labeled AdExos 
provided a background fluorescence signal. Consistent with our microscopy, in the PGAT injected with 
labeled AdExos, adipocytes were not fluorescent above background (Figure 3.2). In fact, almost all of the 
PKH26 signal in the injected PGAT was in the SVC fraction (Figure 3.2). This indicated that AdExos were 
being taken up by non-adipocytes in the PGAT. The SVC fraction was further characterized using FACS. 




CD11b (a myeloid cell marker), and F4/80 (a macrophage marker) and then sorted by a flow cytometer. 
Analysis revealed that >85% of the cells that contained PKH26 fluorescence were CD45+, CD11b+, and 
F4/80+ (Figure 3.3) consistent with the vast majority of the cells that take up AdExos being ATMs (Figure 
3.4). 
 
Exosomes are well known for their signaling capabilities, and these particular AdExos have also 
been shown to contain large amounts of lipid. To elucidate the effects these vesicles might have on the 
macrophages that take them up, we moved to an in vitro system. Bone marrow-derived macrophages 
(BMDMs) provide a plentiful source that can be used to investigate the cellular behavior of primary 
macrophages. Bone marrow cells are taken from young mice and differentiated into mature 
macrophages, in culture, using colony-stimulating factor 1 (CSF-1) and associated factors. Previous work 
in our laboratory demonstrated that co-culture of bone marrow cells with adipose tissue (or conditioned 
medium from adipose tissue) and CSF-1 induces the differentiation of ATM-like cells. 
 
Naïve BMDMs were cultured with PKH-26-labeled AdExos to investigate their effects on 
macrophage cell biology. Using confocal microscopy, it was clear that the BMDMs were taking up 
AdExos, as their F4/80+ cell bodies were labeled with PKH-26 (Figure 3.5). AdExo treatment was also 
sufficient to induce significant lipid accumulation within the BMDMs as evidenced by BODIPY staining 
within the macrophages (Figure 3.5). Of note, only PKH26+ BMDMs displayed the increased BODIPY 
staining. These AdExo-treated BMDMs were examined using targeted lipidomics to determine how 
AdExos altered the lipid make up of macrophages. Mass spectrometry revealed that BMDMs treated with 
AdExos had the same relative molar amounts of lipid species as untreated BMDMs, except for a large 
increase in the amount of TAG (Figure 3.6). AdExo-treated BMDMs contained roughly eight-fold more 






Figure 3.1. AdExos Taken up by F4/80+ Cells in PGAT. Confocal microscopy images of whole PGAT 
mounts. Lepob/ob PGAT was injected with PKH26-labeled AdExos and stained with fluorescently-
conjugated antibody against F4/80. Scale bars represent 20µm.  
 
Figure 3.2. In Adipose Tissue AdExos are Taken Up by Non-adipocytes. PKH26 Fluorescence of 
adipocyte and SVC lysates from PGAT injected with phosphate-buffered saline (PBS) (left) or PKH26-





Figure 3.3. AdExo-Injected SVC FACS. Representative Flow Cytometry gating of SVCs from PGAT 
injected with PBS (top) or PKH26-labeled AdExos (bottom).  
 
 
Figure 3.4. AdExos are Taken up by Macrophages in PGAT. Percent PKH26+ SVCs that are CD45.2+ 
CD11b+ F4/80hi macrophages is quantified for PBS-Inj and AdExo-Inj groups (Inj, injected), as 












Figure 3.5. AdExos Induce Neutral Lipid Accumulation in BMDMs. Confocal microscopy images of in 
vitro-generated BMDMs cultured with PKH26-labeled AdExos and immunostained with antibodies against 
F4/80 (blue), as well as DNA fluorescent stain DAPI (white) and neutral lipid fluorescent stain BODIPY 





Figure 3.6. AdExo-Treated BMDM Lipidomics. Targeted lipidomics of Untreated or AdExo-treated 








As discussed earlier, the typical pathway of TAG accumulation in cells occurs through the re-
esterification of free fatty acids (FFAs) (23). FFAs are taken up by cells and attached to glycerol 
backbones through the action of diglyceride acyltransferases, DGAT1 and DGAT2 (24, 25).  AdExos 
contain relatively little FFA (Figure 2.22) but high concentrations of TAG (Figure 2.23). However, to 
formally confirm that TAG accumulation occurred through uptake of intake AdExo TAG and not through a 
hydrolysis and re-esterification process or re-esterification of FFAs associated with AdExos, BMDMs were 
pre-treated with inhibitors of DGAT1 and DGAT2, before being incubated with AdExos. Using confocal 
microscopy, we saw that F4/80+ BMDMs still accumulated large amounts of neutral lipid (Figure 3.7). 
This finding was confirmed using enzymatic assays, where DGAT inhibitors had no measurable effect on 
the acylglyceride content of AdExo-treated BMDMs (Figure 3.8). This is a particularly interesting finding 
considering that treating BMDMs with FFA is able to induce TAG accumulation in BMDMs (Figure 3.9). 
Incidentally, direct FFA treatment induced a significant amount of BMDM death, a finding that was not 
reproduced when treating BMDM with AdExos. Overall, these data indicate that while macrophages are 
capable of accumulating TAG via esterification of FFAs, TAG accumulation in BMDMs by AdExos occurs 















Figure 3.7. AdExos Lead to Neutral Lipid Accumulation in BMDMs Independent of DGAT Activity. 
Confocal microscopy images of in vitro-generated BMDMs pre-treated with inhibitors against DGAT1 and 
DGAT2 activity, before being cultured with AdExos and immunostained with antibodies against F4/80 
(blue), as well as DNA fluorescent stain DAPI (white) and neutral lipid fluorescent stain BODIPY (green). 
Scale bars, 10 mm. 
 
 
Figure 3.8. AdExos Transfer Acylglyceride to BMDMs Independently of DGAT Activity. Triglyceride 
levels of BMDMs cultured alone, with DGAT1/2 Inhibitors, with AdExos, or with both DGAT1/2 Inhibitors 
and AdExos for 24 hours, measured enzymatically. One-way ANOVA; n = 6; *** p-value < 0.001. 
 
 
Figure 3.9. FFA Treatment Induces TAG Accumulation in BMDMs. Confocal microscopy images of in 
vitro-generated BMDMs treated with FFA and immunostained with antibodies against F4/80 (blue), as 
well as DNA fluorescent stain DAPI (white) and neutral lipid fluorescent stain BODIPY (green). Scale 





Exosome uptake can occur through several different pathways that include direct fusion with the 
recipient cell’s plasma membrane, receptor-mediated lipid raft endocytosis, or non-receptor-mediated 
endocytosis mechanisms, including phagocytosis or macropinocytosis (26). Macrophages are 
professional phagocytes characterized by their proclivity to take up pathogens and extracellular material 
through actin-driven protrusions (8). It is therefore possible that AdExos are being taken up via 
phagocytosis or macropinocytosis, processes that are dependent upon PI3K activity (9, 27). To test this 
hypothesis, BMDMs were pre-treated with a PI3K inhibitor before AdExo treatment. The acylglyceride 
content of the BMDMs was determined using enzymatic assays. The macropinocytosis inhibitor had no 
effect on the TAG content of untreated BMDMs. However, AdExo-treated BMDMs had significantly 
reduced TAG content when the cells were pre-treated with the inhibitor (Figure 3.10). These data indicate 
that the ability for macrophages to macropinocytose is necessary to induce the lipid accumulation that 
occurs upon AdExo treatment. 
 
Some interesting observations were made in AdExo-treated BMDMs when investigating the lipid 
accumulation. The first is that BMDMs that were treated with AdExos often contained more than one 
nucleus, as determined by DAPI staining and confocal microscopy (Figure 3.11). This phenomenon of 
multinucleation is commonly seen in primary ATMs. Additionally, AdExos appeared to be sufficient to 
induce increased lysosomal content in BMDMs, as evidenced by increased acidic compartment content of 










Figure 3.10. Macropinocytosis is Necessary for AdExo-Induced Acylglyceride Accumulation in 
BMDMs. Triglyceride levels of BMDMs cultured alone, with 100 mM LY294002, with AdExos, or with both 




Figure 3.11. AdExos Induce Multinucleation in BMDMs. Confocal microscopy images of in vitro-
generated BMDMs cultured with AdExos and immunostained with antibodies against F4/80 (blue), as well 







Figure 3.12. AdExos Increase Acidic Compartment Content of BMDMs. Confocal microscopy images 
of in vitro–generated BMDMs either cultured alone (top), with WT PGAT (middle), or with AdExos 
(bottom) for 3 days, immunostained with antibodies against F4/80 (blue), as well as DNA fluorescent stain 
DAPI (white), neutral lipid fluorescent stain BODIPY (green), and acidic organelle stain LysoTracker (red). 
Scale bars, 10 mm. 
 
 
Figure 3.13. AdExos Increase Lysosomal Protein Content of BMDMs. Western blots of protein 
isolated from untreated BMDMs (left) or AdExo-treated BMDMs (right). Blots were probed using 









Increased lysosomal content, multinucleation, and increased TAG content are all hallmarks of 
primary ATMs, suggesting that AdExos when added to CSF-1-treated bone marrow cells could induce 
differentiation towards an ATM-like cell. To investigate the effects on the transcription profile of AdExo-
treated BMDMs, naïve BMDMs were either untreated, co-cultured with PGAT, treated with AdExos, 
treated with PGAT conditioned medium depleted of AdExos, or treated with exosomes from primary 
osteoblast cultures for six days (Figure 3.14). RNA was taken from the cells and analyzed using 
quantitative PCR.  
 
The first set of genes we studied were “ATM Genes”. Several RNAseq studies have been done 
on macrophage populations from various murine tissues in an effort to understand the differences 
between the populations and identify markers that distinguish macrophage populations (28-30). “ATM 
Genes” are a selection of genes that have been found to be highly expressed in ATMs, when compared 
to other macrophage populations (31-33). We tested whether ATM genes are induced in BMDMs by co-
culture with PGAT and found that compared to BMDMs without exposure to PGAT explants, adipose 
tissue did induce these genes (Figure 3.15). We next treated BMDMs with AdExos during differentiation 
and found AdExos contained the factors that induced ATM gene expression, but that these genes do not 
increase when BMDMs are treated with filtrate (PGAT conditioned medium that has been depleted of 
AdExos) or with exosomes isolated from irrelevant cells: primary osteoblast cultures (OsbExos). This 













Figure 3.14. BMDM Treatment Protocol. 
 
 
Figure 3.15. AdExos Induce Upregulation of ATM Genes in BMDMs. Quantitative polymerase chain 
reaction for BMDMs cultured alone, with WT PGAT, with AdExos, with filtrate from PGAT-conditioned 
medium (AdExos removed), or with exosomes secreted from primary osteoblasts (OsbExos) for 6 days. 













Next, we looked at how AdExos altered the expression of genes whose products are involved in 
lipid binding, transport, metabolism, and action (Figure 3.15). Fatty acid binding protein 4 (Fabp4) is 
elevated in ATMs and thought to be important in intracellular lipid trafficking and to be upregulated as the 
lipid content of a cell increases. BMDMs upregulate this gene in response to PGAT co-culture, AdExo 
treatment, and to the FFA-containing filtrate treatment. Cd36 is a fatty acid receptor on the exterior of 
macrophages that facilitates transport of FFA across the plasma membrane. Cd36 expression is 
upregulated in response to PGAT co-culture and filtrate treatment, but expression is not increased in 
response to AdExo treatment. This supports the hypothesis that AdExo-induced TAG accumulation is not 
acting through FFA uptake. Srebp1c, a gene that encodes a transcriptional regulator of TAG is modestly 
increased in BMDMs cultured in the presence of adipose tissue, but not by AdExos (Figure 3.15). The 
BMDM response to AdExos does not seem to be a generalized “tissue resident-like” polarization, as they 
do not induce changes in expression of “Kupffer Cell Genes” (Figure 3.16). The last thing to note here is 
that this response to AdExos does not seem to be a general response to any exosomes, as OsbExos do 
not induce the same expression patterns in BMDMs. 
 
As a short aside, OsbExos have a wider distribution of particle diameter than AdExos (Figure 
3.17, Supplemental Figure 3.2). Treatment of BMDMs with OsbExos did not induce TAG accumulation in 
F4/80+ cells (Figure 3.18). We also examined “Osteoclast Genes” in our qPCR experiment, to investigate 
whether OsbExos were capable of inducing gene expression profiles consistent with primary osteoclasts, 
the tissue resident macrophages of the bone. The results from this section of the experiment were difficult 
to interpret. Certain “Osteoclast Genes” were upregulated in response to OsbExo treatment, whereas 
others were not (Figure 3.19). In addition, some genes that were induced by OsbExos, were also induced 





Figure 3.16. AdExos Do Not Induce Kupffer Cell Gene Expression in BMDMs. Quantitative 
polymerase chain reaction for BMDMs cultured alone, with WT PGAT, with AdExos, with filtrate from 
PGAT-conditioned medium (AdExos removed), or with exosomes secreted from primary osteoblasts 
(OsbExos) for 6 days. One-way ANOVA; n = 3 to 5; Error bars represent SD. 
 
 
Figure 3.17. Osteoblast-Derived Exosome Size Distribution. Viewsizer 3000 Nanoparticle Tracking 
Analysis histogram of exosomes purified from primary osteoblast conditioned medium, depicting particle 






Figure 3.18. OsbExos Do Not Induce Neutral Lipid Accumulation in BMDMs. Confocal microscopy 
images of AdExo-treated or OsbExo-treated BMDMs. Cells were immunostained with antibodies against 
F4/80 (blue), as well as DNA fluorescent stain DAPI (white) and neutral lipid fluorescent stain BODIPY 




Figure 3.19. OsbExos Do Not Induce Osteoclast-Like Gene Expression Profile. Quantitative 
polymerase chain reaction for BMDMs cultured alone, with AdExos, or with exosomes secreted from 





To delve further into ATM-like differentiation in response to AdExos, RNAseq experiments were 
performed on BMDMs that were either differentiated only with CSF-1, differentiated with CSF-1 in the 
presence of PGAT, or differentiated with CSF-1 and AdExos. Density plots of the sequencing data 
revealed a similar distribution of reads per base, indicating that the sample could be compared (Figure 
3.20). Principal Component Analyses (PCA) were performed to assess whether two component analysis 
of transcripts distinguished BMDMs from AdExo and PGAT conditioned medium treated BMDMs (Figure 
3.21). Untreated BMDM samples clustered together tightly and clearly separated themselves from the 
AdExo-treated and PGAT co-cultured BMDMs which clustered quite closely to one another. 
 
Co-culturing with PGAT upregulated 1344 genes with a nominal p-value < 0.001 compared to 
untreated BMDMs. Of these 1334 genes, 1032 of them were also upregulated in BMDMs treated with 
AdExos, representing 77% of upregulated genes. 1077 genes were downregulated by PGAT co-culture 
and of these 881 were also downregulated by AdExo treatment, representing 82%. Magnitude of 
expression abundance was plotted with heat maps for genes significantly upregulated by PGAT co-
culture (Figure 3.22) and genes significantly downregulated (Figure 3.23). Consistent with the small 
selection of genes we assessed by qPCR previously treatment with AdExo and PGAT conditioned 











Figure 3.20. BMDM RNAseq Density Plots. Reads per base count density plots for RNA from Untreated 
(AS001, AS002, AS003), PGAT-co-cultured (AS004, AS005, AS006), and AdExo-treated (AS007, AS008, 
AS009) BDMDMs.  
 
 
Figure 3.21. BMDMs Treated with AdExos Cluster with BMDMs Co-Culture with PGAT. Projection of 
samples onto two dimensions of principal components for untreated (blue lines), PGAT-co-cultured 






Figure 3.22. RNA Abundance Heat Map for Genes Upregulated by PGAT Co-Culture. Heatmap of 





Figure 3.23. RNA Abundance Heat Map for Genes Downregulated by PGAT Co-Culture. Heatmap of 

















The 1000 genes with the lowest nominal p-values when comparing expression between BMDMs 
and BMDMs differentiated in the presence of AdExos were analyzed using Enrichr to determine whether 
the expression of genes in functional pathways were overrepresented (Figure 3.24). The two most 
enriched pathways both involve response to cholesterol. There are several gene pathways that involve 
changes to immune signaling, and there are also several pathways that are heavily involved in adipose 
tissue, including leptin and insulin signaling and white fat cell differentiation pathways. Genes altered by 
AdExo treatment are most associated with blood, not surprising as BMDMs are bone marrow-derived, 
and adipose tissue (Figure 3.25). And lastly, as far as subcellular components are concerned, these 
genes are most associated with lysosomes and vesicle membranes, consistent with the increase in 
lysosomes seen by microscopy (Figure 3.26). These transcriptional signatures are consistent AdExo-
treated BMDMs activating programs for the uptake and lysosomal degradation of lipid-laden exosomes.   
 
To better understand the relationship of BMDMs differentiated in the presence of AdExos with 
authentic primary ATMs, we isolated resident and recruited ATMs and performed RNAseq. The primary 
ATMs were divided between long-lived resident macrophages, identifiable by high expression of the 
macrophage marker F4/80 macrophages and recruited/transient macrophages, that express  F4/80 at low 
levels. F4/80lo and F4/80hi macrophages were isolated from both lean and high fat fed obese mice (30). 
PCA plots showed that BMDMs clustered separately from either population of primary ATMs (Figure 
3.27), although a distinction was still clear between AdExo/PGAT BMDMs and untreated BMDMs. 
Hierarchical clustering of samples based on transcriptional profile yields similar results, with some 












Figure 3.24. AdExo-Induced BMDM Gene Pathways. Common pathways associated with top 1000 
differentially expressed genes in AdExo-treated BMDMs. 
 
Figure 3.25. AdExo-Induced BMDM Gene Tissues. Tissues associated with top 1000 differentially 





Figure 3.26. AdExo-Induced BMDM Gene Subcellular Structures. Cellular components associated 












Figure 3.27. BMDMs and Primary ATMs Cluster Separately. Projection of samples onto two 
dimensions of principal components for untreated (BMDM), PGAT-co-cultured (CondMed.BMDM) and 
AdExo-treated (AdExo.BMDM) BMDMs along with primary f4/80hi ATMs from high fat diet- 
(F480hi.2wkHFD) and chow-fed (F480hi.Chow) animals and primary f4/80lo ATMs from high fat diet- 






Figure 3.28. BMDMs Treated with AdExos are More Similar to Primary ATMs than Untreated 
BMDMs. Jensen-Shannon divergence hierarchy for untreated (BMDM), PGAT-co-cultured 
(CondMed.BMDM) and AdExo-treated (AdExo.BMDM) BMDMs along with primary f4/80hi ATMs from 
high fat diet- (F480hi.2wkHFD) and chow-fed (F480hi.Chow) animals and primary f4/80lo ATMs from high 











Genes significantly upregulated in each population compared to untreated BMDMs were matched 
to establish pathways that define ATM-ness (Figure 3.29). In this analysis, AdExo treated BMDMs were 
more similar to F4/80lo than F4/80hi primary ATMs. A common set of 301 genes were significantly 
upregulated in AdExo and PGAT treated BMDMs, F4/80lo, and F4/80hi ATMs compared to untreated 
BMDMs. Pathway enrichment analysis found 43 programs upregulated in the in vitro and authentic ATMs, 
representing a wide variety of processes  (Figure 3.30). Several programs associated with lipid 
metabolism and immune responses were in this group, but of note were pathways associated with 
angiogenesis and cell proliferation, programs that are consistent with the recently reported role of ATMs 
in adipose tissue expansion. Downregulated genes told a similar story, where 345 genes were 
significantly inhibited in all four “ATM-like” cell populations (Figure 3.31). These genes seem to be 
involved heavily in cholesterol synthesis, which would be an appropriate response given the high content 













Figure 3.29. Genes Upregulated Compared to Untreated BMDMs. JVenn diagram displaying shared 
genes, significantly upregulated compared to BMDMs, in PGAT co-cultured (cond.med UP), AdExo-
treated (ad.exo UP) BMDMs and primary f4/80lo ATMs (f480lo chow UP) and f480hi ATMs (f480hi chow 





Figure 3.30. Gene Pathways Upregulated in All ATM-Like Cells. List of common pathways associated 
with genes, significantly upregulated compared to BMDMs, in PGAT co-cultured (cond.med UP), AdExo-
treated (ad.exo UP) BMDMs and primary f4/80lo ATMs (f480lo chow UP) and f480hi ATMs (f480hi chow 
UP) from chow-fed animals. 
cytokine-mediated signaling pathway (GO:0019221)
cellular response to cytokine stimulus (GO:0071345)
response to lipid (GO:0033993)
response to lipopolysaccharide (GO:0032496)
response to molecule of bacterial origin (GO:0002237)
regulation of cell proliferation (GO:0042127)
positive regulation of leukocyte chemotaxis (GO:0002690)
positive regulation of angiogenesis (GO:0045766)
positive regulation of vasculature development (GO:1904018)
chemokine-mediated signaling pathway (GO:0070098)
negative regulation of STAT cascade (GO:1904893)
regulation of angiogenesis (GO:0045765)
cellular response to hormone stimulus (GO:0032870)
positive regulation of cellular process (GO:0048522)
negative regulation of apoptotic process (GO:0043066)
negative regulation of JAK-STAT cascade (GO:0046426)
inflammatory response (GO:0006954)
negative regulation of programmed cell death (GO:0043069)
positive regulation of transcription, DNA-templated (GO:0045893)
positive regulation of transcription from RNA polymerase II promoter (GO:0045944)
negative regulation of insulin receptor signaling pathway (GO:0046627)
positive regulation of cell differentiation (GO:0045597)
negative regulation of cellular response to insulin stimulus (GO:1900077)
regulation of transcription from RNA polymerase II promoter (GO:0006357)
regulation of JAK-STAT cascade (GO:0046425)
regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043122)
positive regulation of cell proliferation (GO:0008284)
positive regulation of cell motility (GO:2000147)
cellular response to interleukin-1 (GO:0071347)
regulation of cell migration (GO:0030334)
regulation of natural killer cell chemotaxis (GO:2000501)
positive regulation of cell migration (GO:0030335)
cellular response to interleukin-7 (GO:0098761)
interleukin-7-mediated signaling pathway (GO:0038111)
regulation of insulin receptor signaling pathway (GO:0046626)
cellular response to hypoxia (GO:0071456)
cellular response to tumor necrosis factor (GO:0071356)
cellular response to organic substance (GO:0071310)
regulation of transcription, DNA-templated (GO:0006355)
STAT cascade (GO:0097696)
membrane lipid biosynthetic process (GO:0046467)





Figure 3.31. Genes Downregulated in Comparison to Untreated BMDMs. JVenn diagram displaying 
shared genes, significantly downregulated compared to BMDMs, in PGAT co-cultured (cond.med UP), 
AdExo-treated (ad.exo UP) BMDMs and primary f4/80lo ATMs (f480lo chow UP) and f480hi ATMs (f480hi 





Figure 3.32. Gene Pathways Downregulated in All ATM-Like Cells. List of common pathways 
associated with genes, significantly downregulated compared to BMDMs, in PGAT co-cultured (cond.med 
UP), AdExo-treated (ad.exo UP) BMDMs and primary f4/80lo ATMs (f480lo chow UP) and f480hi ATMs 













We found that AdExos were capable of inducing an ATM-like differentiation in naïve BMDMs in 
vitro. To test whether AdExos would be able to induce ATM-ness in mature cells in vivo, we treated 
peritoneal cells with AdExos. PKH26-labeled AdExos were injected into the peritoneal cavity of lean mice. 
After 24 hours, these mice were sacrificed and peritoneal cavity cells (PC cells) were isolated from the 
animals. These PC cells were then sorted using flow cytometry. Interestingly, the PKH26 exosomal 
marker was taken up almost exclusively by macrophages in this tissue as well, with >90% of PKH26+ 
cells also expressing F4/80 (Figure 3.33). Peritoneal macrophages from AdExo-injected animals and 
those from PBS-injected animals were sorted and RNA was collected. Quantitative PCR was performed 
to measure the same genes that were examined in the BMDM studies. The results revealed that several 
of the “ATM Genes” that were upregulated in BMDMs treated with AdExos, were also upregulated in PC 
macrophages injected with AdExos, but others were not (Figure 3.34). Marco, a “Kupffer Cell Gene” was 
strongly induced in PC macrophages from animals injected with AdExos. Interestingly, lipid-associated 
genes were not upregulated by AdExo injection, perhaps because the lipid takes some time to 
accumulate. AdExos were able to partially induce the ATM-like profile in in vivo cells, however they were 
not able to fully differentiate PC macrophages into ATMs. This does not provide definitive evidence about 
the ability of AdExo to alter the phenotype of other tissue macrophages.  
 
Taken together the data in this chapter suggest that AdExos can help shape macrophage 
phenotype. We have found that AdExos are taken up primarily by macrophage populations in the PGAT 
and are sufficient to induce TAG accumulation, multinucleation, increased lysosomal content, and a gene 
expression profile consistent with primary ATMs. Thus, AdExos may be a critical signal in the 






Figure 3.33. AdExos Are Taken up by Peritoneal Cavity Macrophages. Representative flow cytometry 
analysis of peritoneal cavity cells isolated from animals that were injected with either PKH26-labeled 
adipocyte-derived exosomes or PBS. Histograms show number of PKH26+ cells in CD45+, CD11b-hi, 
F4/80-hi (blue) and CD45+, CD11b-lo, F4/80-lo (red) cell populations. Data is summarized in bar graphs. 





Figure 3.34. AdExos Do Not Induce ATM-Like Differentiation in Peritoneal Cavity Macrophages. 
Gene expression of peritoneal cavity cells isolated from animals that were injected with either PKH26-
labeled adipocyte-derived exosomes or PBS. After 24 hours, cells were isolated from mice and sorted by 
flow cytometry, before isolating RNA and performing quantitative PCR (top) and BMDMs untreated or 
treated with AdExos for 25 hours before isolating RNA and performing quantitative PCR (bottom). 
Unpaired, two-tailed T-Test; n=4. *P < 0.05, **P < 0.01, ***P < 0.001; Error bars represent SD. 
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CHAPTER 4:EXPLORING MECHANISMS THAT CONTROL ADIPOSE TISSUE-DERIVED EXOSOME 




Obesity is a growing epidemic in the US and the world. Obesity is described as a state of excess 
body fat with expansion of adipose tissue. Roughly 40% of the US population is currently obese, and it is 
expected that 50% of the US population will be obese by 2030 (1-3). Obesity is associated with many 
complications, including atherosclerosis, type 2 diabetes mellitus (T2DM), and cancers, all contributing to 
premature death (4-7). The mechanism as to how obesity contributes to its complications is unknown. 
Although increasing BMI is correlated with one’s risk for developing these diseases, there remain certain 
populations of extremely obese individuals with normal metabolic health and no indications of heart 
disease or cancer development (8). Understanding the how obesity increases morbidity and mortality 
would provide the opportunity to develop better therapies to treat obesity-associated disorders.  
 
Some of the leading theories of the pathogenesis of obesity’s co-morbidities include adipose 
tissue inflammation and ectopic lipid deposition (9). The former focuses on the finding that as obesity 
progresses, the number of macrophages in adipose tissue grows significantly (10). The amount of 
inflammation in adipose tissue correlates very strongly with one’s risk for developing insulin resistance, a 
relationship that is even stronger than the relationship between insulin resistance risk and BMI (11-15). 
Several groups have found that inflammatory signaling is capable of inducing insulin resistance in 
energetic cells, however anti-inflammatory interventions for T2DM have been largely unsuccessful (16-
18). 
 
Another possible player in the pathogenesis of the co-morbidities of obesity is ectopic lipid 
deposition. Triglyceride storage in ectopic (non-adipose tissue) depots is a common symptom of obesity 
(19). The phenomenon has also been shown to correlate very strongly with risk for T2DM, 
atherosclerosis, and fatty liver disease (9, 19-22). The mechanism of action is thought to be carried out by 




symptom in a targeted fashion have yet to be identified, however, exercise has been shown to clear 
ectopic depots of triglyceride and increase insulin sensitivity in those tissues (26-28). 
 
Obesity is assuredly a very complex disorder and affects the homeostasis of many different organ 
systems, but seems to particularly center around the adipose tissue. Obesity can have dramatic effects in 
adipose tissue, including drastic changes in the compositions of cell-types contained within it and in the 
architecture of its parenchymal cells (29, 30). During obesity adipocytes can grow ~20-fold in diameter, 
increasing their lipid stores by several thousand-fold (31). Obesity has been shown to significantly alter 
much of the adipokine signaling from adipocytes (32, 33). Obesity is also known to increase baseline free 
fatty acid release from adipocytes and can induce insulin resistance in adipocytes, themselves (20). 
 
Given that obesity induces adipose tissue macrophage accumulation, increased lipid release from 
adipocytes, and non-adipocyte triglyceride deposition, determining whether AdExos react to obesity is 
particularly relevant, having shown that AdExos are taken up by adipose tissue macrophages and can 
induce triglyceride accumulation in non-adipocytes.  
 
To determine whether the triglyceride content of AdExos is increased in the state of obesity, 
PGAT was taken from WT and leptin-deficient Lepob/ob mice and cultured for 16 hours. AdExos were 
isolated from the conditioned medium and analyzed using enzymatic assays. AdExos released from 
obese PGAT were determined to contain ~2.5 µmol of acylglyceride per gram of tissue, released every 
hour (Figure 4.1). This is equivalent to ~0.1% of the total acylglyceride content of the tissue and over 
twice the amount that is released from lean PGAT (Figure 4.2). The total mass of PGAT from the leptin-
deficient mice is roughly six times as large (Figure 4.3). Acylglyceride measurements for AdExos are 
normalized by tissue mass and adipocytes are typically much more massive in the state of obesity, 
indicating that the amount of AdExo acylglyceride per adipocyte is likely increased even more than 2-fold 





To determine how AdExo lipid composition is altered in the obese state, targeted lipidomics was 
performed on AdExos from lean and obese PGAT. Surprisingly, the lipid profiles of obese AdExos were 
very similar to lean AdExos, with some minor differences in sphingomyelin and free cholesterol 
concentrations (Figure 4.4). The relative molar amounts of lipids in the AdExos, largely did not change, 
even the relative amounts of tri- and mono-acylglycerides (Figure 4.4). This was particularly interesting, 
considering the increased total acylglyceride being released from obese PGAT (Figure 4.2). Thus, we 








Figure 4.1. Obesity increases the amount of acylglyceride released in AdExos from PGAT by two-
fold. Acylglyceride content of exosomes isolated from the PGAT of WT or Lepob/ob mice, expressed per g 





Figure 4.2. Obese PGAT releases 0.1% of total acylglyceride content in AdExos. Acylglyceride 
content of purified adipocyte-derived exosomes from WT or Lepob/ob PGAT, expressed as a percentage of 




Figure 4.3. Obese PGAT is more massive than lean PGAT. Mass of total PGAT removed from WT and 






Figure 4.4. Obese AdExos have similar lipid content profile to lean AdExos. Targeted lipidomics of 
adipocyte-derived exosomes isolated from WT and Lepob/ob mouse PGAT. Unpaired, two-tailed T-Test; 






Obese PGAT was found to release ~3.5x1011 exosomes per gram of tissue per hour (Figure 4.5). 
This number, again, was more than twice the amount released from lean PGAT and seems sufficient to 
explain the discrepancy in total acylglyceride released. On the macro-scale, the relative amounts of lipids 
within a single AdExo doesn’t change from lean state to obese state, however, the number of particles 
released doubles, and therefore so does the total amount of acylglyceride contained within AdExos. The 
size distribution of AdExo particles from obese PGAT also looks very similar to those from lean tissue 
(Figure 4.6). There is perhaps a small rightward shift in the distribution, indicating slightly more particles 
with larger diameters in the obese AdExo samples, however the mean diameter of obese AdExos (115 +/- 
54nm) was smaller than mean diameter of lean AdExos (118 +/- 57nm). The median of the obese AdExo 
distribution was 104nm, whereas the median diameter for lean AdExos was 102nm. Overall, obese 
AdExos and lean AdExos were strikingly similar (Supplemental Figure 4.1). 
 
If obesity can be considered as the state of energy overabundance, fasting can be considered the 
state of energy underabundance. To determine whether fasting would have any effect on AdExo release 
rates, mice were fasted for 16 hours overnight. PGAT was harvested from these animals and cultured for 
16 hours. AdExos were isolated and investigated using enzymatic assays and nanoparticle tracking 
analysis. AdExo acylglyceride content was significantly increased in fasted animals, even more so than 
obese animals (Figure 4.7). This was once again accompanied by a proportional increase in AdExo 
number (Figure 4.8). The size distribution of AdExos from fasted PGAT was very similar to those from 
lean fed PGAT, with a mean diameter of 112 +/- 60 nm and a median diameter of 101 nm (Figure 4.9). 
These data seem to indicate that in the fasting and obese states, the structure of exosomes being 






Figure 4.5. Obese PGAT secretes more AdExos. Quantification of exosomes released by adipose 
tissue per gram per hour from adipose tissue from lean and Lepob/ob mice, as measured by Nanoparticle 






Figure 4.6. Obese AdExo size distribution. Nanoparticle tracking analysis histogram of purified adipose 
tissue-derived exosomes, depicting particle diameter and the number of particles at each diameter 








Figure 4.7. Fasting increases acylglyceride released in AdExos. Acylglyceride content of exosomes 
isolated from PGAT of lean mice fed ad lib or fasted for 16 hours, expressed per g of tissue per hour. 
Unpaired two-tailed t test; n = 8; **P < 0.005. Error bars represent SD. 
 
 
Figure 4.8. Fasting increases AdExo release rate. Quantification of exosomes released by adipose 
tissue per gram per hour from PGAT of WT fed and fasted mice, as measured by Nanoparticle Tracking 






Figure 4.9. Fasting Viewsizer Profile. Viewsizer 3000 Nanoparticle Tracking Analysis histogram of 
purified adipose tissue-derived exosomes from WT fasted mice, depicting particle diameter and the 



















The fact that AdExo release is increased by both fasting and obesity is fairly interesting. In terms 
of understanding the mechanisms that control release, these two findings alone would indicate that 
AdExo release rate is not defined by energetic need, at least not solely, nor is it set by cell size. 
Interestingly, in both fasting and obesity, adipocyte lipolysis is known to increase, so it is possible that 
AdExo release is controlled by the same or similar signaling pathways that control lipid release as free 
fatty acids (34-38).  
 
To identify potential physiological mechanisms of AdExo release, PGAT explants were treated 
with various pharmacological compounds. These compounds included common metabolic signaling 
hormones, such as insulin and glucagon, which has been previously shown to impact exosome release 
from adipose tissue (39). Drugs for the treatment of T2DM, like Rosiglitazone were used, as well as 
adrenergic stimulators, like CL 243,316. Surprisingly, no treatments to PGAT explants have induced any 
changes in the number of AdExos released from the tissue (Figure 4.10). CL 243,316 treatment was 
capable of increasing lipolysis in the PGAT explants, but had no effect on AdExo release, indicating that 
AdExo release rate is not determined by adrenergic stimulation (Figure 4.11, Figure 4.12). 
 
We have seen that both obesity and fasting can lead to increased release of acylglyceride in 
AdExos (Figure 4.1, Figure 4.7). We have also seen that AdExos are taken up primarily by F4/80+ 
macrophages in the adipose tissue (Figure 3.4), and that they are capable of inducing neutral lipid 
accumulation in naïve BMDMs (Figure 3.5). To identify the effects of fasting and obesity on ATMs in vivo, 
primary stromal vascular cells were isolated from obese PGAT, and lean PGAT fed ad lib or fasted for 16 
hours. These SVCs were investigated using confocal microscopy and ATMs from obese or fasted mice 
were found to contain increased neutral lipid (Figure 4.13). This finding is consistent with previous data in 
supporting the hypothesis that AdExos are capable of transporting triglyceride to local macrophages and 







Figure 4.10. AdExo release rate not affected by metabolic hormones. Quantification of exosomes 
released by adipose tissue per gram per hour from WT PGAT explants. Explants were untreated or 
treated with insulin, glucagon, or rosiglitazone. Measurements were made by Viewsizer 3000 
Nanoparticle Tracking Analysis. Error bars represent SD.  
 
 
Figure 4.11. CL-Treatment increases PGAT FFA release. Free fatty acid content of PGAT conditioned 
medium cultured untreated or with CL-243,316 for 16 hours per gram per hour. Unpaired two-tailed t test; 







Figure 4.12. CL-Treatment does not affect AdExo release from PGAT. Quantification of exosomes 
released by adipose tissue per gram per hour from WT PGAT explants. Explants were untreated or 
treated with CL-243,316. Measurements were made by Viewsizer 3000 Nanoparticle Tracking Analysis. 















This raises the question of whether endogenous AdExos are capable of escaping the adipose 
tissue and being taken up by cells in other tissues. To begin answering these questions, we made a 
transgenic mouse that expresses the fluorescent marker protein tdTomato specifically in adipocytes 
(Figure 4.14). TdTomato protein was detectably expressed in adipocyte-tomato-expressing (AdTom) 
PGAT, and undetectable in WT (Figure 4.15). TdTomato protein was not present in the adiponectin-
lacking stromal vascular cells of AdTom PGAT (Figure 4.15). And tdTomato was present in AdExos 
derived from AdTom PGAT (Figure 4.15). The fluorescence of the tdTomato was also detectable in 
AdTom AdExos using fluorescent spectrophotometry, whereas WT AdExos contained no such 
fluorescence, again confirming that some portion of the AdExos are derived from adipocytes (Figure 
4.16). 
 
To determine the rough proportion of exosomes released by adipose tissue that are derived from 
adipocytes, AdExos were isolated from AdTom PGAT and measured via fluorescent spectrophotometry 
and nanoparticle tracking analysis to establish a ratio of fluorescence per exosome. AdTom PGAT was 
then separated into its adipocyte and non-adipocyte (SVC) fractions. These cells were cultured, AdExos 
were isolated from the conditioned media, and the AdExos were analyzed in the same way to determine 
the ratio between tdTomato fluorescence and exosome count. As was expected exosomes released from 
AdTom SVCs had nearly no detectable fluorescence per exosome (Figure 4.17). AdTom adipocyte 
cultures released exosomes with roughly similar amounts of fluorescence per exosome as whole AdTom 












Figure 4.13. Obesity and fasting increases ATM neutral lipid content. Confocal microscopy images of 
primary stromal vascular cells that were isolated from Lepob/ob (bottom), or WT fed (top) and fasted 
(middle) mice. SVCs were plated and immunostained with antibodies against F4/80 (blue), as well as 











Figure 4.15. TdTomato protein is contained within AdTom AdExos. Western blot of total protein from 
whole AdTom PGAT, WT PGAT, SVCs isolated from AdTom PGAT, and AdExos isolated from AdTom 
PGAT. Blots were probed using antibodies against tdTomato and bActin. 
 
 
Figure 4.16. AdTom AdExos contain tdTomato fluorescence. Relative tdTomato fluorescence of 
AdExos isolated from control (Cre-) or AdTom (Cre+) PGAT in which the fluorescent protein was either 
not expressed (Cre-) or expressed specifically in adipocytes (Cre+). Unpaired two-tailed t test; n = 4; *** 






Serum samples were taken from AdTom mice to establish whether AdExos are escaping into 
circulation. Circulating exosomes were isolated from AdTom serum samples and western blotting 
revealed the presence of tdTomato protein within the exosome fraction (Figure 4.18). This confirmed that 
AdExos were escaping adipose tissue and contributing to the circulating exosome population. As a rough 
quantitative measure, the ratio of CD63 (canonical exosomal marker) to tdTomato protein content was 
calculated for exosomes from PGAT explants vs exosomes from circulation. Explant-derived AdExos 
contained an ~11-fold higher tdTomato/CD63 ratio compared to those from circulation (Figure 4.19), 
indicating that they represent a minority of the lipid species in circulation. 
 
Efforts to detect tdTomato outside of adipose tissue have been fruitless. As mentioned above, 
even SVCs within AdTom PGAT, which are known to take up AdExos, contained no detectable signal 
(Figure 4.15). If AdTom AdExos are also labeled with PKH67 fluorescence before they are added to 
BMDMs, PKH67 can be easily identified within the cells, whereas no tdTomato fluorescence or protein 
signal can be detected in the cells (Figure 4.20). Our best hypothesis to explain this phenomenon is that 
the tdTomato protein is being degraded. AdExos have been shown to be taken up via macropinocytosis 
(Figure 3.10), which means they likely go through an endosomal/lysosomal pathway. It is possible that 
certain cytosolic proteins in the AdExos are degraded, while membrane-bound dyes, like PKH67 are 
protected from macrophage degradation. This investigation is ongoing and efforts to overcome this 
obstacle are discussed in the next chapter. 
 
Taken together these data seem to suggest that AdExo release is controlled by energy status. 
Both obesity and fasting can increase the number and total acylglyceride content of exosomes released 
from PGAT. The physiological mechanism through which this control take place remains unknown. And 
we have seen that AdExos can be taken up locally by macrophages, but also escape the tissue and enter 








Figure 4.17. Majority of AdExos are adipocyte-derived. TdTomato fluorescence per exosome, as 
measured by nanoparticle tracking analysis, for AdExos purified from whole AdTom PGAT, adipocytes 
isolated from AdTom PGAT, and SVCs isolated from AdTom PGAT. One-way ANOVA; n = 4, **P < 0.01, 
***P < 0.001. 
 
Figure 4.18. TdTomato protein contained within AdTom circulating exosomes. Western blot of total 
protein from AdExos isolated from AdTom PGAT, AdExos isolated from WT PGAT, exosomes isolated 
from AdTom serum, and exosomes isolated from WT serum. Blots were probed using antibodies against 





Figure 4.19. AdExos represent minority of circulating exosomes. Quantification of protein content of 
AdExos isolated from AdTom PGAT explants and serum samples, as determined by Western blot. Values 
are expressed as a relative ratio of tdTomato protein to CD63 protein. Unpaired two-tailed t test; n = 2; *** 


























Figure 4.20. BMDMs do not contain tdTomato fluorescence after taking up AdTom AdExos. PKH67 
and tdTomato fluorescence of AdExos and BMDMs, as measured by fluorescence spectrophotometer. 
AdExos were isolate from AdTom PGAT explants and labeled with PKH67, before being measured for 
PKH67 and tdTomato fluorescence. Naïve BMDMs untreated or treated with these labeled AdExos and 
then measured for PKH67 and tdTomato fluorescence.  
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We have seen that, in addition to the FFA released during normal lipolysis, adipocytes are also 
capable of releasing whole TAG in exosomes (AdExos). This pathway of release is controlled, in some 
way, by obesity and fasting, but occurs independently from adipocyte lipase activity. AdExos are taken up 
at high rates by local macrophages in the PGAT. AdExos are sufficient to induce neutral lipid 
accumulation and an ATM-like gene expression profile in naïve macrophages. We have also seen that 
AdExos can leave PGAT and enter the circulation, though, whether they are picked up by or interact with 
cells outside of adipose tissue remains unknown (Figure 5.1). 
 
Adipose tissue-derived exosomes in the circulation are not new. Many studies have reported 
adipocyte proteins and miRNA contained within circulating exosomes (1-3). The key questions, regarding 
our findings, are whether or not circulating AdExos contain neutral lipid, and whether they contribute to 
circulating triglyceride in any meaningful way. There have been some difficulties in getting to the bottom 
of these questions. Because of the high lipid content of AdExos, traditional, density-based purification 
strategies for exosomes proved inefficient. We were able to develop a size-fractionation strategy to 
effectively isolate AdExos from PGAT explant cultures. This purification process, however, presents 
problems when faced with isolating exosomes from serum, as circulating particles of similar size are 
isolated along with exosomes. Indeed, we have found that ApoB-containing particles are contained within 








Figure 5.1. Graphical summary of AdExo actions. 
 
 
Figure 5.2. Serum AdExo fractions contain ApoB protein. Western blots of protein from exosomal 
fractions isolated from mouse serum (Serum Exos) or PGAT explants (AdExos), and protein isolated 











We are presently working on alternate methods of purification to answer the circulating AdExo-TG 
question. Magnetic bead pulldowns with antibodies against adipocyte membrane proteins have proved 
inefficient, possibly because of low concentrations of adipocyte membrane proteins expressed on each 
exosome. Current efforts are focused on using a genetic mouse model, called the MetRS* mouse to 
robustly label AdExos, specifically. These mice have a floxed mutant Methionyl tRNA Synthetase gene. 
When expressed under an adipocyte-specific Cre recombinase, this mutant tRNA synthetase allows for 
Azidonorleucine (ANL) to be incorporated into proteins any time a methionine residue would be added to 
the protein (4-6). This amino acid substitution has no effect on protein function, but effectively 
incorporates a label onto all proteins translated in adipocytes (Figure 5.3, [figure modified from 
Hazenpichler et al.]). Azide groups in ANL are capable of undergoing a CLICK reaction with alkyne 
groups, producing a sturdy covalent bond. In these animals every protein on AdExos should contain ANL, 
while exosomes derived from other cells will not. Serum samples can be incubated with alkyne-biotin 
molecules to bind ANL-containing proteins and pull intact AdExos, specifically, out of solution (Figure 
5.4). This would allow for a whole host of investigations to be conducted on in vivo isolated, circulating 














Figure 5.3. MetRS* mouse allows for ANL to be incorporated into proteins.  
 
 





The physiological mechanism controlling AdExo release is a subject of significant interest. As 
mentioned before, both obesity and fasting lead to increased AdExo secretion from PGAT. This indicates 
that AdExo release is not responding specifically to systemic energy need or energy oversaturation. Both 
fasting and obesity are known to induce increased lipolysis in adipocytes, however, reducing lipolysis, 
using genetic models or pharmacological inhibitors, has no effect on AdExos, neither increasing nor 
decreasing the amount released. Furthermore, systemic metabolic signals, such as insulin and glucagon, 
that are known to have dramatic effects on lipolysis rates, have no effect on AdExo release (7-9). These 
data suggest that AdExo release is not a response to systemic metabolic status and further distance this 
lipid release pathway from canonical lipolysis. 
 
Some data that could potentially shed light on potential mechanisms are the preliminary data on 
AdExos released from different adipose tissue depots. Perigonadal (PGAT) and subcutaneous (SubQ) 
adipose tissues are both white fat depots that play a similar role in the body, though they differ in several 
important factors: PGAT is more innervated, and contains more immune cells than SubQ, and SubQ 
depots have a lesser capacity for pre-adipocyte differentiation, and adipocytes are typically larger than in 
PGAT (10).  The intrascapular brown adipose tissue depot (BAT), however has very distinct roles 
compared to white adipose tissues. BAT’s main role is thermogenic. It achieves this goal by burning fatty 
acids through beta-oxidation, but instead of producing ATP, mitochondrial membrane leak through the 
action of uncoupling protein 1 (UCP1), produces heat (11-13). Using NTA, we find that BAT explants 
release the most AdExos per gram of tissue, 1.5-fold more than PGAT, and 3-fold more than SubQ 
depots (Figure 5.5). BAT AdExos and SubQ AdExos are smaller than those released from PGAT (Figure 
5.6). Interestingly, however, BAT AdExos contain, by far, the least amount of TAG, with SubQ AdExos 
also containing less TAG than PGAT AdExos (Figure 5.7). These data require more in-depth exploration, 








Figure 5.5. BAT releases more AdExos per gram than PGAT. Quantification of exosomes released by 
subcutaneous (SubQ), perigonadal (PGAT) and brown (BAT) adipose tissue explants, per gram of tissue 
per hour. Measurements were made by Viewsizer 3000 Nanoparticle Tracking Analysis. One-way 
ANOVA; *P < 0.05, **P < 0.01. n = 2. Error bars represent SD. 
 
Figure 5.6. PGAT AdExos have the largest diameter. Average diameter of exosomes released by 
subcutaneous (SubQ), perigonadal (PGAT) and brown (BAT) adipose tissue explants. Measurements 
were made by Viewsizer 3000 Nanoparticle Tracking Analysis. One-way ANOVA; **P < 0.01, ***P < 





Figure 5.7. BAT AdExos contain very little TAG. Acylglyceride content of exosomes released by 
subcutaneous (SubQ), perigonadal (PGAT) and brown (BAT) adipose tissue explants, per exosome. 

































One possible explanation for AdExo release rates reacting to obesity and fasting is that AdExos 
are released as an adipocyte stress response. Chronic obesity and long-term fasting are both known to 
induce a significant amount of stress in adipocytes (14-16). It is possible that AdExos could be released 
as signaling structures to communicate that stress or as a mechanism to off-load unwanted material. 
Exosomes have been shown to be used by cells as a means of offloading misfolded protein (17-19). To 
test this theory, we could induce adipocyte ER stress with pharmacological molecules such as 
thapsigargin or EGTA, and then measure AdExo release in response to those stress stimuli (20, 21). 
 
All of this says nothing about the cell biology of AdExo release, which remains a black box. How 
lipid droplet structure would come to be contained within exosomal vesicles is completely unknown. It is 
possible that pieces of lipid droplet bud off from the central droplet of the adipocyte, creating a structure 
with all of the necessary neutral lipid, phospholipid, and protein components. This process however, 
would be extremely energetically costly, and would likely require cellular machinery that is heretofore 
unknown. Another scenario could involve smaller lipid droplets that eventually fuse with the central lipid 
droplet that are captured before fusion. Lipid droplet materials are trafficked to developing exosomes and 
constructed within the vesicle. There are ways to disrupt exosome secretion, such as using Rab GTPase 
inhibitors, however, almost all of the known proteins involved in exosome secretion also have functions in 
the general endosomal pathway (22, 23). Disrupting these proteins pharmacologically or genetically also 
leads to disruption in cell trafficking, causing cellular dysfunction (24). These methods are therefore not 
ideal in physiological studies; however, they may prove useful tools in unraveling the cell biology of 
AdExo release. 
  
The cell biology of AdExo uptake is also incompletely understood. BMDM neutral lipid uptake 
from AdExos occurs through PI3K-dependent macropinocytosis or phagocytosis. However, there remain 
many questions about the fate of AdExo contents in recipient cells. For example, what happens to the 
non-TAG lipid species in AdExos when added to BMDMs? The lipidomic contents of AdExos are not fully 
represented in the cells that take them up. AdExos, if they are taken up via macropinocytosis or 




lipids may be recycled to the plasma membrane or degraded. The TAG content of AdExos is translated 
very clearly to TAG content in BMDMs, however the AdExo MAG is completely absent in BMDMs. It is 
unlikely that the MAG content of AdExos is re-esterified such that it contributes to TAG accumulation in 
BMDMs as this process would require DGAT, and DGAT inhibition has no effect on the magnitude of TAG 
accumulation in BMDMs. The most likely explanation is that the MAG is hydrolyzed and used for energy 
to fuel the actions of the macrophage. Likewise, AdExos contain very high levels of cholesterol, and many 
of the gene pathways activated in AdExo-treated BMDMs involve response to cholesterol, however, 
BMDM cholesterol content, relative to other lipid species as determined by mass spectrometry, remains 
unchanged compared to untreated BMDMs. 
 
 AdExo uptake is capable of inducing ATM-like gene expression profiles in naïve macrophages. 
The mechanism through which AdExos are able to induce these changes is unknown. Specific mRNA or 
protein contained within AdExos could be having direct effects on BMDM signaling and gene expression. 
The signal could be transduced through lysosome-associated machinery that sample lysosomal 
degradation products to inform the cell. Or the reaction could simply be a response to increased lipid 
content in these cells. Depleting the AdExos of their neutral lipid content, could help distinguish between 
these possibilities. We have seen that AdExos contain PNPLA2/ATGL, whether this lipase is functional is 
also unknown. However, perhaps it would be possible to activate lipolysis in AdExos, depleting the 
vesicles of TAG, before adding them to BMDMs, to see if their reaction changes.  
 
Whatever the mechanism, the evidence is clear that AdExos appear to educate naïve 
macrophages to become more like ATMs. This, of course, raises the question as to whether this is a tool 
utilized by other tissues. Almost all mammalian cell types have been found to secrete exosomes (25). 
Large proportions of circulating exosomes have been shown to be taken up by macrophages, in general 
(26, 27). Is it possible that parenchymal cells throughout the body release exosomes which are taken up 
by newly-replicated or newly-arrived macrophages to inform them of their tissue location? Could these 
parenchymal-derived exosomes promote tissue-specific adaptive functions that could help the tissue 




primary osteoblasts, to see if they become more osteoclast-like. The gene expression response to 
OsbExos in “Osteoclast Genes” were mixed. However, the developmental pathway of osteoclasts is 
actually very well studied, and has been found to require RANK-ligand in order to fully differentiate (28, 
29). How tissue resident macrophages elsewhere in the body develop is not well-understood, and 
exosomal education could be a potential pathway. The effectiveness of the pathway in other tissues 
would be relatively straightforward to investigate by treating naïve BMDMs with exosomes isolated from 
parenchymal cells (hepatocytes, neurons, etc…) and comparing gene expression profiles with those 














Altogether, it remains unclear what purpose this pathway of TAG release in AdExos serves. It 
would seem counterproductive to imagine that AdExos are a means to distribute energy to peripheral 
cells, as the energy required to transport necessary materials and produce the exosomes would likely 
vastly outweigh the cost of canonical lipolysis as a means of distribution. There is a possible advantage to 
the long-lived nature of exosomes, such that they are able to travel great distances through circulation. In 
addition, the extensive membrane and associated proteins could allow for more specific cellular targeting 
than can be generally achieved by FFA release. Perhaps, AdExos are used to transport TAG to specific 
cells to be used for energetic needs. The role of TAG in AdExos could also be purely in signaling.  
 
Another potential hypothesis relates back to the adipocyte stress response discussed earlier. 
Adipocytes are long-lived (~10 years in human) cells that can change size and shape (>20-fold increase 
to cell diameter) dramatically based on lipid content. They need to be able to change size with some 
speed in order to respond to large influxes of lipid, or outfluxes of lipid during fasting. It is likely that 
adipocytes require some amount of maintenance and remodeling, especially during these high-stress 
periods. We also know that the ability of macrophages to hydrolyze lipid is necessary for adipose tissue 
homeostasis, as in LIPA-deficient mice, adipocytes slowly shrink as TAG storage is moved from adipose 
tissue to ectopic depots (30, 31). The adipose tissue lipid cycle hypothesis postulates that adipocytes 
unload TAG and membrane lipids to local macrophages via exosomes, which is then degraded and 
released back to adipocytes to allow for remodeling (Figure 5.9). This process would be upregulated 
when adipocytes need to significantly increase or decrease their size, which results in increased AdExo 
release during obesity and fasting. This proposed cycle is mirrored in the bone, another long-lived tissue 
that requires re-modeling. Osteoclasts, the tissue resident macrophage of the bone degrades mineralized 
bone, releasing bone-building materials that are taken up and remodeled by osteoblasts, the 
parenchymal cell of the bone (Figure 5.10). This process is known to be upregulated in times of high 
remodeling needs, such as bone growth in development, or during physical activity when bone can be 





Whatever their biological function, AdExos may also take part in the development of pathologies. 
Obesity is associated with increased inflammation in the adipose tissue, increased circulating TAG, and 
increased ectopic TAG deposition. Each of those obesity symptoms are, in turn, associated with insulin 
resistance, atherosclerosis, and stroke, many of the main causes of morbidity and mortality in obesity. 
There is a potential role for AdExos in connecting obesity to these co-morbidities. AdExos are largely 
taken up by immune cells in the adipose tissue and are capable of inducing significant changes in those 
cells. AdExos have also been shown to enter circulation. And if AdExos are taken up by non-adipose 
tissue cells, they have already been shown to induce TAG accumulation in cells that take them up. 
 
Much more work needs to be done to understand how AdExos operate biologically. However, if 
AdExos turn out to be involved in these pathological processes, targeting AdExos could be a useful 




















Figure 5.9. Graphical representation of adipocyte remodeling. 
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CHAPTER 6: MATERIALS AND METHODS 
 
Animals and Animal Care  
Male C57BL/6J, B6.FVB-Tg(Adipoq-cre)1Evdr/J and B6.V-Lep/obJ mice were obtained from The Jackson 
Laboratory (Bar Harbor, ME) at ages ranging from 4 to 12 weeks old. Mice harboring a floxed allele of 
Pnpla2/Atgl (C57BL/6NTac) were kindly provided by Erin Kershaw (University of Pittsburgh). Mice with 
adipocyte-specific deletion of Pnpla2/Atgl were generated in the F2 generation of animals from the 
intercrossing of B6.FVB-Tg(Adipoq-cre)1Evdr/J and C57BL/6NTac-Tg(Pnpla2fl/fl) mice. To genotype 
animals, DNA was isolated from tail lysate and PCR was performed using PCR primers as previously 
described (6). Mice were housed in pathogen-free barrier facility, in ventilated cages with free access to 
autoclaved water and low-fat pellet diet (5% calories from fat, PicoLab Rodent Diet 20; Purina Mills Inc). 
Mice were maintained on a 12-hour light/dark cycle and housed with 3-5 male mice per cage. Animal 
procedures were approved by Columbia University Institutional Animal Care and Use Committee.   
 
Isolation and Culturing of Adipose Tissue Stromal Vascular Cells (SVCs) 
Following CO2 asphyxiation and cervical dislocation, mice were dissected and perigonadal adipose tissue 
(PGAT) isolated.  PGAT was placed in FACS buffer (PBS (GIBCO), 0.2% bovine serum albumin (BSA, 
Sigma-Aldrich), and 5mM Ethylenediaminetetracetic acid (EDTA, Sigma-Aldrich)), minced into fine (<10 
mg) pieces. Samples were centrifuged at 500g for 5 minutes at room temperature to pellet debris. Floating 
adipose tissue (AT) fragments were transferred into Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen) 
with 10 mg/mL BSA and digestive enzymes (0.14 units/mL of Liberase TM (Roche Applied Science) and 
50U/mL of DNase I (Sigma-Aldrich)) and digested in a 37°C orbital shaker at 185 rpm for 30 minutes. 
Following digestion, the solution was passed through a sterile 250-µm nylon mesh (Sefar Filtration Inc). 
The suspension was centrifuged for 5 minutes at 500 g at room temperature.  The stromal vascular cells 
(SVCs) pellet was washed by resuspending in FACS buffer and centrifuging once more at 500g for 5 
minutes at room temperature. For immunostaining, SVCs were first plated by resuspending them in culture 
medium (DMEM, 20% L929 cell-conditioned media, 10% fetal bovine serum (FBS, Invitrogen), and 1% 
Penicillin-Streptomycin (P/S, Invitrogen) at a concentration of 500,000 cells/mL. SVCs were cultured 
overnight at 37°C in 4 well chamber slides (LabTek) in 5% CO2 and fresh DMEM was added.  
 
In Vitro Preparation of BMDMs, BM-ATMs, AdExo-induced differentiated cells and Foam Cells 
Bone marrow (BM) cells were collected from femurs of 4-5-week-old wild-type C57BL/6J mice. BM cells 
were plated 50-60x106 cells in a tissue culture flask (175 mL size) at 37°C and 5% CO2 for two days in 100 
ml of BM culture medium (Minimum Essential Medium Alpha (MEM-α, Invitrogen), 10% FBS, 1% Non-
essential amino acids (NEAA, Invitrogen), 1% P/S). After two days, non-adherent cells were collected, 
centrifuged at 500g for 5 minutes, counted, and seeded on cell culture plates (BD Bioscience) or 4 well 




supplemented with 30 ng/mL of colony stimulating factor-1 (CSF-1/M-CSF, R&D systems). After three days 
of differentiation in the presence CSF-1 most cells were adherent and the medium was removed. These 
cells were used for DGAT inhibitor and macropinocytosis inhibitor studies. The cells were further 
differentiated into bone marrow-derived adipose tissue macrophages (BM-ATMs) or AdExo-induced 
differentiated cells. For differentiation of cells into BM-ATMs, 100 mg of PGAT was isolated from 12-week-
old male C57BL/6J male mice and placed in porous tissue inserts (BD Bioscience) with BM-culture medium 
and CSF-1 (30 ng/ml). For AdExo-induced differentiated cells, fresh ad-exos purified from conditioned 
medium of 100 mg of PGAT cultured overnight were added to BM-culture medium every day. EM and 
confocal experiments were carried out after 6 days of PGAT co-culture or AdExo treatment. Gene 
expression data was gathered from macrophages following 10 days of PGAT co-culture, AdExo, or OsbExo 
treatment. Culture medium containing fresh CSF-1 was changed every 3 days. Foam cells were generated 
as previously described (8).  
For each experiment, control bone marrow-derived macrophages (BMDMs) were differentiated using the 
same condition and medium except the medium was not supplemented with AdExo, OsbExo or conditioned 
medium from PGAT.   
 
EM Imaging 
Macrophages - BM-ATMs and BM-foam cells pellets were fixed with 2% paraformaldehyde. Cells were 
embedded, sectioned, stained with Osmium tetroxide and uranyl acetate using standard protocols (REF). 
AdExos -After collecting the exosome fraction from lean or obese adipose tissue conditioned medium, 
paraformaldehyde was added to each sample (2% vol/vol). Samples were air dried on Formvar-carbon-
coated grids, negative stained with uranyl acetate, and washed. Grids were examined under a JEOL JEM-
1200 EXII electron microscope. Images were captured with an ORCA-HR digital camera and recorded with 
image capturing software (AMT Image Capture Engine, Advanced Microscopy Techniques, Corp). 
 
Atglistatin Treatment 
PGAT was cultured for 16 hours in Dulbecco’s Modified Eagle Medium supplemented with 50µM Atglistatin 
(Sigma-Aldrich).  Conditioned medium was collected to measure free fatty acid content, or added to 
BMDMs. BMDM lipid content was visualized using confocal microscopy and BODIPY staining after 24 hours 
or triglyceride concentration was measured using the method described below after 3 hours of incubation.  
 
Free Fatty Acid Treatment 
BMDMs were differentiated for 3 days before being switched to BM Medium (+CSF-1) with 100µM 
Palmitate, 400µM Oleate, and 10mM glycerol. Confocal images were taken after 6 days of free fatty acid 
treatment, medium being changed every 3 days. 
 




Perigonadal Adipose Tissue was taken from 10 - 12-week-old male C57BL/6J, minced to 2mm, and cultured 
in Minimum Essential Medium Alpha (MEM-a, Invitrogen) for a 1-hour pre-culture. Tissue was then washed 
and centrifuged with MEM-a before being cultured in MEM-a for 16 hours. Adipose Tissue was passed 
through a 70µm filter (Greiner Bio-One EASYstrainer) and conditioned medium was collected. The medium 
was then passed through a 0.8µm syringe filter (Sartorius Minisart) and then concentrated via 100kD 
centrifuge filters (Millipore Amicon Ultra – 2mL Centrifuge Filters). Filtrate samples were taken from the 
flow-through of this stage of purification. The concentrated conditioned medium was then either labeled 
with PKH26 (Sigma PKH Red Fluorescent Cell Linker Kit) according to manufacturer’s instructions, or left 
unlabeled. The medium was added to a gel filtration column (Thermo Scientific Disposible 5mL 
Polypropelyne Columns), packed with Illustra Sephacryl S-1000 Superfine Silica Gel (GE Healthcare), 
using PBS as the mobile phase. Fractions containing 30 – 200nm objects (by diameter) were collected and 
once again concentrated using centrifuge filters. Filtrate samples were concentrated via Vacufuge 
(Eppendorf) and matched to exosome samples by volume. After isolation, the fluorescent emission of 
labeled exosomes was measured using a FLUOstar Optima fluorescence spectrophotometer plate reader 
(BMG-Labtech). For BMDM treatment, 1x1010 exosomes were administered per mL culture medium. 
 
Fasting Experiments 
Animals were fasted for 16 hours overnight (5PM – 9AM). At completion of 16hrs tissue was collected and 
cultured for 16 hours before AdExo isolation. 
 
DGAT1/2 Inhibitor Treatment 
BMDMs were pre-incubated with 30µM AZD7679 (AstraZeneca), 10µM PF-06424439 (Tocris) for 1 hour in 
DMEM. BMDMs were then treated with AdExos for 24 hours, for confocal microscopy, or 3 hours, for 
triglyceride assay.  
 
Macropinocytosis Inhibitor Treatment 
BMDMs were pre-incubated with 100µM LY294002 (Sigma-Aldrich) for 1 hour in DMEM. BMDMs were then 
treated with AdExos for 3 hours, and analyzed using triglyceride assay.  
 
Metabolic Signaling Molecule Treatment 
WT PGAT explants were treated with 5 µg/mL insulin, 20 nM glucagon, 1 µM rosiglitazone, or 15 µM CL-
316,243 (Sigma). Exosome number was assessed using Viewsizer 3000 nanoparticle tracking analysis 
after AdExo isolation. For CL-316,243, whole conditioned medium was measured for FFA content using 






For whole tissue visualization, perigonadal adipose tissue was removed from 12-week-old obese (Lep 
ob/ob) mice. The tissue was minced and incubated with 1:1000 v/v anti-F4/80 Rat mAb (Invitrogen), and 
1:1000 v/v Perilipin 2 (D1D8) XP Rabbit mAb (Cell Signaling) overnight at 4oC, and then incubated in 
secondary 1:500 v/v Novex™ Goat anti-Rabbit IgG (H+L) Secondary Antibody, Cy5® conjugate (Invitrogen) 
and 1:500 v/v Goat Anti-Rat IgG (H+L) Secondary Antibody, Cy3 conjugate (Invitrogen) antibodies for two 
hours. The tissue was then stained with 1:300 v/v BODIPY 493/503 (4,4-Difluoro-1,3,5,7,8-Pentamethyl-4-
Bora-3a,4a-Diaza-s-Indacene, Thermofisher Scientific) and 1:4000 v/v DAPI (Thermofisher Scientific) 
fluorescent stains for 5 minutes, before washing and visualizing on Nikon A1R MP confocal microscope. 
Bone-marrow-derived cells were cultured on chamber well slides, fixed in 2% paraformaldehyde, before 
primary and secondary antibody staining. The cells were washed and then stained with fluorescent stains 
1:300 v/v BODIPY, 1:4000 v/v DAPI, and 5mM Lysotracker (Invitrogen) at 37oC for 30 minutes. 
 
Triglyceride Assay 
Measuring of triglyceride content in isolated exosomes, tissue, and BMDMs was done using Abcam’s 
Triglyceride Quantification Kit, according to the manufacturer’s protocol.  
 
Nanoparticle Tracking Analysis 
Purified exosome samples were analyzed for particle concentration and size distribution using nanoparticle 
tracking analysis method by Malvern NanoSight NS300 (Malvern Instruments Ltd, Malvern, United 
Kingdom), or ViewSizer 3000 (MANTA Instruments, Horiba Scientific). The assays were performed 
according to the recommended protocols of each  manufacturer. Briefly, for the NanoSight, three 
independent replicates of diluted exosome preparations in PBS were injected at a constant rate into the 
tracking chamber by the provided syringe pump. The specimens were tracked at room temperature for 60s. 
Shutter and gain were manually adjusted for optimal detection and were kept at optimized settings for all 
samples. The data were captured and analyzed with NTA Build 127 software (version 2.2, Malvern 
Instruments Ltd, Malvern, UK). For the Viewsizer 3000, 50 15s tracking measurements were captured at 




After isolation, PGAT, BM-derived cells, and exosomes samples were resuspended in tissue extraction 
reagent I (Invitrogen) with protease inhibitor cocktail (Sigma-Aldrich).  Samples were homogenized using a 
stainless-steel bead homogenizer. Protein concentrations were measured using a BIO-RAD Protein Assay 
(BIO-RAD) and 20-50 µg of protein were denatured at 96°C for 5 minutes in 4x protein sample buffer (200 
mM Tris 6.8, 8% sodium dodecyl sulfate, 0.4% Bromophenol blue, 40% glycerol, and 5% β-
mercaptoethanol). Protein was loaded on 10-15% SDS-polyacrylamide gels and ran at 100-140 volts for 2-




Scientific) with a wet transfer system (BIO-RAD) for 45 minutes.  Membranes were blocked with 5% non-
fat milk solution and incubated with primary antibodies overnight at 4°C: anti-CD63 (System Biosciences), 
anti-HSP70 (System Biosciences), anti-CD9 (System Biosciences), anti-CAV1 (Cell Signaling), anti-FABP4 
(Abcam), anti-COXIV (Cell signaling), anti-Lamin B1 (Abcam), anti-β-actin (Sigma-Aldrich), anti-
PNPLA2/ATGL (Cell signaling), anti-LAMP2 (Abcam). Membranes were washed with Tri-Buffered Saline 
Tween-20 (TBST) and incubated with secondary antibodies either HRP conjugated (Abcam) for ECL 
chemiluminescence detection system (G&E science) development or fluorescent antibodies for LICOR 
odyssey system (LICOR) development. 
 
Proteinase Treatment 
Purified ad-exos were isolated from WT PGAT conditioned medium. These exosomes were exposed in 
suspension to either 100µg/mL of recombinant, PCR grade, Proteinase K (Sigma), 0.5% v/v Triton-X100, 
or both for 15 minutes on ice. After exposure, all samples were incubated with 1mM PMSF proteinase 
inhibitor (Sigma) for 15 minutes, before undergoing normal Western blotting protocol as described above. 
 
Lipidomics Studies 
Purified AdExos or BMDMs were treated with 2:1(v/v) chloroform:methanol, 1mM butylated 
hydroxytoluene, and 500 nmol of deuterium-labeled lipid standard with stainless steel beads. The sample 
was sonicated for 30 min at room temperature before being centrifuged at 13000rpm for 10min at 4oC. 
The sample was dried completely under nitrogen and then reconstituted with DMSO. Sample was 
analyzed via LC-MS/MS. Lipid extracts were spiked with appropriate internal standards, and analyzed 
using an Agilent 1200 HPLC system coupled with an Applied Biosystem Triple Quadrupole/Ion Trap mass 
spectrometer (3200Qtrap). The protocols were described previously (24).  
 
Quantitative PCR 
Total RNA was extracted from tissues, cells, and exosomes using RNeasy mini-kits (Qiagen). First-strand 
cDNA was synthesized using Superscript III reverse transcriptase and random hexamers (Invitrogen). 
Quantitative RT-PCR assays were carried out using DNA Engine Opticon 2 system instruments (BIORAD) 
and PCR SYBR Green I QuantiTect Master Mix (Qiagen). Data were normalized to Rps3 using the ΔΔC(t) 
method, when presented as relative transcript levels. All primers used are listed in Table S1. 
 
RNAseq Analysis 
Primary ATMs were sorted using flow cytometry. Total RNA was isolated from untreated BMDMs, AdExo-
treated BMDMs, BMDMs co-cultured with PGAT, F4/80hi primary ATMs from chow-fed animals, F4/80hi 
primary ATMs from high fat diet-fed animals, F4/8lo primary ATMs from chow-fed animals, and F4/80lo 




using Bioanalyzer. Sequencing of isolated RNA was performed by the Columbia Genome Center, using the 
Illumina HiSeq 2500. 
 
Primary Osteoblast Culture 
Calvaria from newborn mice (P2-P5) were collected, washed in PBS, and pre-digested in collagenase 
digestion solution (58 U/mL Collagenase Type 2 (Worthington), 2.5% Trypsin-EDTA, in MEMa) at 37oC, 
shaking, for 20 min. Medium was removed and re-incubated with collagenase digestion solution at 37oC, 
shaking, for 60 min. Cells were washed and cultured in Osb Culture Medium (MEMa, 10% FBS, 1% P/S, 
4mM L-Glutamine). After 2 days, the cells were trypsinized and passed through a 70µm strainer. Cells were 
then cultured with Osb Culture Medium + 5mM Glycerol 2 Phosphate and 0.1mg/mL Ascorbic Acid. 




Whole perigonadal adipose tissue from 16-week ob/ob animals was injected with 30µL and roughly 1x1010 
PKH26-labeled exosomes, immediately following removal from the animal. After a one-hour incubation in 
MEMa, the tissue was then digested with Liberase and centrifuged to separate adipocyte and SVC 
fractions. Both fractions were lysed and their PKH26 fluorescence measured using a fluorescent 
spectrophotometer. SVCs were also utilized for FACS analysis. 
 
Peritoneal Cavity Macrophage Isolation 
30µL of PKH26-labeled ad-exos or PBS were injected into the peritoneal cavity of 8-week old WT C57BL/6J 
mice. 24 hours later, the mice were sacrificed. The skin on the ventral side of the animal was opened and 
5 mL ice-cold FACS Buffer was injected into the peritoneal cavity. The peritoneum of the animal was 
massaged, before the injected buffer was re-collected using a syringe. The collected buffer was spun for 8 
min at 1500rpm to pellet cells. The peritoneal cavity cells were then washed and resuspended in FACS 
buffer for flow cytometry or cell sorting. 
 
FACS Analysis 
SVCs were pelleted and resuspended in FACS buffer with 2% Fc Block (BD Bioscience) and placed on 
rotator for 30 minutes at 4°C in dark. Fluorophore-conjugated antibodies were added for 30 minutes at 4°C 
on rotator: 1:100 v/v eFluor 660-F4/80 antibody (AbD Serotec), 1:100 v/v anti-CD11b-FITC antibody 
(Invitrogen), and 1:100 v/v anti-CD45.2-PerCP-Cy5.5 antibody (Invitrogen).  Cells were washed twice with 
FACS buffer centrifuged at 1600 rcf for 3 minutes and resuspended in FACS buffer with (4',6-Diamidino-2-
Phenylindole, Dihydrochloride) (DAPI, Invitrogen). Cells were analyzed using a Fortessa Flow Cytometer 







Statistical analyses were performed as described in the figure legend for each experiment. Data is 
presented as mean ± standard deviation. The indicated sample size (n) represents biological replicates. 
Statistical significance was determined by Student’s t test, one- and two-way ANOVA with post-hoc X tests 
using Graphpad Prism 7 and R. Significance was set at *:P < 0.05. 
 
 
